Identification Effects Of Protein Kinase C Activation In Neurons Under Physiological And Degenerative Conditions by Koç, Şirin Korulu
  
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
ISTANBUL TECHNICAL UNIVERSITY  GRADUATE SCHOOL OF SCIENCE 
ENGINEERING AND TECHNOLOGY 
Ph.D. THESIS 
NOVEMBER 2012 
 
IDENTIFICATION EFFECTS OF PROTEIN KINASE C ACTIVATION IN 
NEURONS UNDER PHYSIOLOGICAL AND DEGENERATIVE CONDITIONS 
Şirin KORULU KOÇ 
Department of Advanced Technologies 
 
Molecular Biology – Genetics and Biotechnology Programme 
 
 
 
Anabilim Dalı : Herhangi Mühendislik, Bilim 
Programı : Herhangi Program 
 
  
  
 
    
NOVEMBER 2012 
 
ISTANBUL TECHNICAL UNIVERSITY  GRADUATE SCHOOL OF SCIENCE 
ENGINEERING AND TECHNOLOGY 
IDENTIFICATION EFFECTS OF PROTEIN KINASE C ACTIVATION IN 
NEURONS UNDER PHYSIOLOGICAL AND DEGENERATIVE CONDITIONS 
 
Ph.D. THESIS 
Şirin KORULU KOÇ 
 (521062206) 
Department of Advanced Technologies 
 
Molecular Biology – Genetics and Biotechnology Programme 
 
 
 
Anabilim Dalı : Herhangi Mühendislik, Bilim 
Programı : Herhangi Program 
 
Thesis Advisor: Prof. Dr. Arzu KARABAY KORKMAZ 
   
   
 
    
KASIM 2012 
İSTANBUL TEKNİK ÜNİVERSİTESİ  FEN BİLİMLERİ ENSTİTÜSÜ 
NÖRONLARDA FİZYOLOJİK VE DEJENERATİF KOŞULLAR ALTINDA  
PROTEİN KİNAZ C AKTİVASYONUNUN ETKİLERİNİN ARAŞTIRILMASI  
 
DOKTORA TEZİ 
Şirin KORULU KOÇ 
(521062206) 
İleri Teknolojiler Anabilim Dalı 
 
Moleküler Biyoloji – Genetik ve Biyoteknoloji Programı 
 
 
 
Anabilim Dalı : Herhangi Mühendislik, Bilim 
Programı : Herhangi Program 
 
Tez Danışmanı: Prof. Dr. Arzu KARABAY KORKMAZ 
    
   
 
 
    
v 
 
Thesis Advisor :  Prof. Dr. Arzu KARABAY KORKMAZ  
 İstanbul Technical University  
Jury Members :  Prof. Dr. Melek ÖZTÜRK                       ..................... 
Istanbul University 
Prof. Dr. Selma YILMAZER                      ..................... 
Istanbul University 
 
Şirin Korulu Koç, a Ph.D. student of ITU Graduate School of Science 
Engineering and Technology student ID 521062206 successfully defended the 
thesis entitled “IDENTIFICATION EFFECTS OF PROTEIN KINASE C 
ACTIVATION IN NEURONS UNDER PHYSIOLOGICAL AND 
DEGENERATIVE CONDITIONS”, which she prepared after fulfilling the 
requirements specified in the associated legislations, before the jury whose signatures 
are below. 
 
 
Date of Submission :  7   September 2012 
Date of Defense :  19 November 2012  
 
Assist.Prof. Dr. Gizem DİNLER DOĞANAY   ..................... 
Istanbul Technical University 
 
Assoc.Prof. Dr. Eda TAHİR TURANLI          ..................... 
Istanbul Technical University 
 
    
vi 
 
 
    
vii 
 
 
 
 
 
To my father, 
 
 
 
    
viii 
 
 
    
ix 
 
FOREWORD 
I would like express my most sincere gratitude to my supervisor Prof. Dr. Arzu 
Karabay Korkmaz for invaluable guidance, advice, and also for her motivation and 
morale support at difficult times. Her understanding, encouraging, stimulating 
advices and personal guidance have provided a strong basis for this thesis.  
I want to express my deep appreciation to Ayşegül Yıldız-Ünal for her valuable 
friendship.  
I would like to express my special gratitude to my family starting with my dear 
father, rest in peace, Seyit Korulu, my mother Şafiye Korulu and my sister Şermin 
Korulu who have always been my biggest inspirations. They have always been there 
for me.  
Finally, my husband Ersin Koç and my little son, Ersin Kaan Koç, who are the most 
important and enjoyable part of my life. 
I would also like to acknowledge the funding agencies. I was funded by scholarship 
from The Scientific and Technological Research Council of Turkey, TUBİTAK-
BİDEB-2211 and this study was funded by grants to Arzu Karabay from The Turkish 
Academy of Sciences (TUBA)-GEBIP, TUBITAK-TBAG (108T811) and İTÜ BAP. 
 
 
 
November  2012 
 
Şirin KORULU KOÇ 
 
 
 
 
 
 
 
 
 
 
 
    
x 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
    
xi 
 
TABLE OF CONTENTS 
Page 
FOREWORD ............................................................................................................. ix 
TABLE OF CONTENTS .......................................................................................... xi 
ABBREVIATIONS .................................................................................................. xv 
LIST OF TABLES ................................................................................................. xvii 
LIST OF FIGURES ................................................................................................ xix 
SUMMARY ........................................................................................................... xxiii 
ÖZET ..................................................................................................................... xxvii 
1. INTRODUCTION .................................................................................................. 1 
1.1 Neurons .............................................................................................................. 1 
1.1.1 Cell cycle markers in mitotic cells and in neurons ..................................... 2 
1.1.1.1 Cell cycle markers in neurodegeneration ............................................. 3 
1.1.1.2 Cell cycle markers in differentiation .................................................... 4 
1.1.2 Amyloid beta in physiological neurons ...................................................... 5 
1.1.2.1 Amyloid beta and PKC interaction ...................................................... 6 
1.2 Protein Kinase C (PKC) Protein Family ............................................................ 7 
1.2.1 Nuclear activities of PKC ........................................................................... 9 
1.2.2 PKC-α ....................................................................................................... 10 
1.2.2.1 PKC-α regulation ............................................................................... 11 
A. Phosphorylation ..................................................................................... 11 
B. Co-factor binding................................................................................... 11 
1.2.3 Roles of PKC-α ......................................................................................... 12 
1.2.3.1 Roles of PKC-α in proliferation and differentiation .......................... 12 
1.2.3.2 Roles of PKC-α in cell cycle regulation............................................. 12 
1.3 Aim of the Study .............................................................................................. 13 
2. MATERIALS AND METHODS ........................................................................ 15 
2.1 Materials ........................................................................................................... 15 
2.1.1 Animals ..................................................................................................... 15 
2.1.2 Antibodies used in this study .................................................................... 15 
2.1.3 Buffers and solutions ................................................................................ 16 
2.1.3.1 Tris buffer saline ................................................................................ 16 
2.1.3.2 Tris buffer saline – Tween20 ............................................................. 16 
2.1.3.3 Towbin buffer..................................................................................... 16 
2.1.3.4 Immunofluorescence blocking buffer ................................................ 16 
2.1.3.5 Western blotting blocking buffer ....................................................... 17 
2.1.3.6 Western blotting stripping buffer ....................................................... 17 
2.1.3.7 PMA solution ..................................................................................... 17 
2.1.3.8 Gö6976 solution ................................................................................. 17 
2.1.3.9 Amyloid beta (1-42) solution ................................................................ 17 
2.1.4 Primary hippocampal neuron culture media ............................................. 18 
2.1.4.1 Hippocampus dissection medium ...................................................... 18 
    
xii 
 
2.1.4.2 Hippocampal plating medium ............................................................ 18 
2.1.4.3 Hippocampal serum free plating medium .......................................... 18 
2.1.5 Cell line media .......................................................................................... 18 
2.1.5.1 Mouse 3T3 fibroblast medium ........................................................... 18 
2.1.5.2 SH-SY5Y neuroblastoma medium ..................................................... 18 
2.1.6 Chemicals .................................................................................................. 19 
2.1.7 Commercial kits ........................................................................................ 20 
2.1.8 Primer and probe sets used in quantitative real time PCR ........................ 20 
2.1.9 Gene assays used in quantitative real time PCR ....................................... 21 
2.1.10 Laboratory equipment ............................................................................. 22 
2.2 Methods ............................................................................................................ 22 
2.2.1 Primary hippocampal neuron culture ........................................................ 22 
2.2.1.1 Dissection of the hippocampus .......................................................... 23 
2.2.2 Cultivation of mouse 3T3 fibroblast or SH-SY5Y neuroblastoma cells ... 24 
2.2.3 Culture dish and coverslip coating ............................................................ 25 
2.2.4 PKC activation and inhibition ................................................................... 26 
2.2.5 Amyloid beta 1-42 pre-incubation ............................................................... 26 
2.2.6 Amyloid beta 1-42 treatment ....................................................................... 26 
2.2.7 Quantitative real time PCR and relative quantification of expression ...... 27 
2.2.8 Immunofluorescence staining of neurons and confocal microscopy ........ 27 
2.2.9 Congo red staining of neurons and light microscopy ................................ 28 
2.2.10 Protein extraction, subcellular fractionation and Western blot ............... 28 
2.2.11 Proliferation and apoptosis analysis ........................................................ 29 
2.2.12 Integrative pixel analysis ......................................................................... 30 
2.2.13 Neuronal process analysis ....................................................................... 30 
2.2.14 Statistical analysis ................................................................................... 31 
3. RESULTS .............................................................................................................. 33 
3.1 Effects of PKC Activation in Hippocampal Neurons ....................................... 33 
3.1.1 PMA and Gö6976 treatments in 3T3 fibroblast cells ................................ 33 
3.1.2 PKC-α distribution analysis in PKC activated hippocampal neurons ....... 33 
3.1.3 Effects of PKC activation in mRNA levels of cyclins and cdks ............... 35 
3.1.4 Analysis of protein levels and distibutions of cyclins in PMA treated 
neurons ....................................................................................................... 37 
3.1.5 CyclinD1 analysis in hippocampal neurons upon PMA mediated PKC 
activation .................................................................................................... 41 
3.1.6 Analysis of pRb and ppRb protein levels upon PKC activation and 
inhibition .................................................................................................... 43 
3.1.7 Morphological analysis of hippocampal neurons...................................... 44 
3.1.8 Determination of p-tau and p60-katanin levels upon PKC activation ...... 46 
3.1.9 Phosphorylation analysis of GSK3β upon PMA treatment ....................... 46 
3.1.10 Proliferation and apoptosis analysis in PMA treated neurons................. 47 
3.2 Effects of PKC Activation in Amyloid Beta Treated Hippocampal Neurons .. 49 
3.2.1 Observation of amyloid beta plaques in hippocampal neurons ................. 49 
3.2.2 Expression level and subcellular distribution analysis of PKC-α upon 
PKC activation in amyloid beta treated neurons ....................................... 50 
3.2.3 Effects of PKC activation on mRNA levels of cyclins in amyloid beta 
treated hippocampal neurons ..................................................................... 51 
3.2.4 Analysis of protein levels and distibutions of cyclinD1 in amyloid beta 
treated hippocampal neurons ..................................................................... 52 
    
xiii 
 
3.2.5 Analysis expression level and subcellular distribution of pRb upon 
PKC activation in amyloid beta treated neurons ....................................... 53 
3.2.6 Morphological analysis of amyloid beta treated hippocampal neurons .... 54 
3.2.7 Analysis expression level and subcellular distribution of p-tau,  p60-
katanin and GSK3β upon PKC activation in amyloid beta treated 
neurons ...................................................................................................... 55 
3.2.8 PKC activation triggered neither proliferation nor apoptosis in amyloid 
beta treated neurons ................................................................................... 56 
4. DISCUSSION AND CONCLUSIONS ............................................................... 59 
REFERENCES ......................................................................................................... 65 
APPENDICES .......................................................................................................... 73 
APPENDIX A ........................................................................................................ 75 
APPENDIX B ........................................................................................................ 77 
APPENDIX C ........................................................................................................ 83 
CURRICULUM VITAE .......................................................................................... 85 
 
 
 
 
    
xiv 
 
    
xv 
 
 
ABBREVIATIONS 
 
BCA : Bicinchoninic acid 
BSA : Bovine serum albumin 
cDNA : Complementary deoxyribonucleic acid 
DAPI : 4',6-diamidino-2-phenylindole 
DIV  : Day in vitro 
DMSO : Dimethyl sulfoxide  
DNA : Deoxyribonucleic acid 
dNTP  : Deoxyribonucleotide 
FBS : Fetal bovine serum 
GAPD : Glyceraldehyde 3-phosphate dehydrogenase 
Gö6976 : 12-(2-Cyanoethyl)-6,7,12,13-tetrahydro-13-methyl-5-oxo- 
5H-indolo [2,3-a]pyrrolo[3,4-c] 
HEPES : 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid 
HRP 
NFTs 
: Horse radish peroxidase 
: Neurofibrillary tangles  
PKC : Protein kinase C 
PMA : Phorbol 12-myristate 13-acetate 
pRb : Retinoblastoma protein 
ppRb : Phosphorylated retinoblastoma protein 
RNA : Ribonucleic acid 
SDS : Sodium dodecyl sulfate 
SDS-PAGE : Sodium dodecyl sulphate-polyacrylaimde gel electrophoresis 
SPSS : Statistical package for the social sciences statistical analysis 
program 
Tris : Tris(hydroxymethyl)aminomethane 
μg : Microgram 
μl  : Microliter 
μM  : Micromolar 
    
xvi 
 
    
xvii 
 
LIST OF TABLES 
Page 
Table 2.1 : Primary antibodies…………………………………………….… 15 
Table 2.2 : Secondary antibodies…………………...………………………. 16 
Table 2.3 : Chemicals……………………………………………………….. 19 
Table 2.4 : Commercial kits…………………………………………………. 20 
Table 2.5 : Primer and probe sets……………………………………………. 20 
Table 2.6 : Gene assays……………………………………………………… 21 
Table 2.7 : Laboratory equipment…………………………………………… 22 
Table A.1 : qRT-PCR efficiency and error rate values………………………. 75 
Table B.1 : qRT-PCR data for PMA treated neurons generated by relative                  
expression software tool………………………………………… 77 
Table B.2 : qRT-PCR data for Gö6976 treated neurons generated by relative 
expression software tool………………………………... 
 
78 
Table B.3 : qRT-PCR data for 1h Gö6976 followed by 23h PMA treated 
neurons generated by relative expression software tool……….... 
 
79 
Table B.4 : qRT-PCR data for 24h amyloid beta treated neurons generated 
by relative expression software tool……………………….……. 
 
80 
Table B.5 : qRT-PCR data for 24h amyloid beta and 24h PMA treated 
neurons generated by relative expression software tool………… 
 
81 
Table C.1 : : Data comparison for the different experimental conditions……... 83 
 
    
xviii 
 
 
    
xix 
 
LIST OF FIGURES 
Page 
Figure 1.1 : Simplified model of a neural stem cell. ................................................... 1 
Figure 1.2 : Microtubule orientation in a typical neuron.  .......................................... 2 
Figure 1.3 : Schematic representation of the eukaryotic cell cycle.  .......................... 3 
Figure 1.4 : FISH applied to AD brain neurons for chromosome 11. Confocal   
image of a hippocampal neuron from an AD brain. Arrows indicate    
the presence of four bright spots of fluorescence in the nuclei, 
suggesting a doubling of the number of chromosomes 11 in this cell. ... 4 
Figure 1.5 : Illustration of PKC – Amyloid interaction. ............................................. 7 
Figure 1.6 : PKC translocation dependent pathways .................................................. 7 
Figure 1.7 : Classification and structure of PKC isoforms ......................................... 8 
Figure 1.8 : Proposed activation model for PKC. ....................................................... 9 
Figure 1.9 : Possible interactions of PKC-α with other signaling pathways ............ 10 
Figure 1.10 : Phosphorylation sites of PKC-α .......................................................... 11 
 
Figure 2.1 : Hippocampus dissection ........................................................................ 25 
  
Figure 3.9 : CyclinD1 analysis in hippocampal neurons upon PMA treatment. (a) 
mRNA levels of cyclinD1 (cycD) in PKC activated (PMA) and 
inhibited (Gö6976) hippocampal neurons were quantified by qRT-
PCR. Calculations were performed according to ΔΔCT method, 
where expression of control is accepted 1 (red line). Bar represents 
mean values ± SEM. * p< 0.05. (b) Western blot of total protein 
lysate of control and PKC activated (PMA) hippocampal neurons (b, 
left). Lysates were separated with SDS-PAGE and probed with cycD 
and actin antibody. Quantitative analysis of the blots (b, right). Band 
intensities were normalized against actin. Bar represents mean values 
± SD. * p< 0.05. (c) Treated hippocampal neurons immunolabeled 
for cycD (red in the lover panel; grey in the upper panel) and neuron 
specific βIII tubulin (green). Scale Bar, 14.5 µm. (d) Western blot of 
cytoplasmic and nuclear protein fractions of control and PKC 
activated (PMA) hippocampal neurons (left). Membrane was probed 
with cycD antibody and Histone3 or actin antibodies as an internal 
control. Quantitative analysis of the blots (right). Band intensities of 
cycD were normalized against actin for cytoplasmic fraction, and 
Histone3 for nuclear fraction. Bar represents mean values ± SD. ........ 42 
Figure 3.10 : Analysis of pRb and ppRb protein levels in hippocampal neurons 
after PMA and Gö6976 treatments. (a) Treated hippocampal neurons 
immunolabeled for pRb (red in the lover panel; grey in the upper 
panel) and neuron specific βIII tubulin (green). (b) Integrative pixel 
analysis of the blots. (c) Total protein lysate of control and PKC 
    
xx 
 
activated (PMA) hippocampal neurons were separated with SDS-
PAGE and probed with pRb, ppRb and actin antibody. (d) 
Quantitative analysis of the blots was performed by normalizing 
band intensities against actin. Bar represents mean values ± SD. * p< 
0.05. ....................................................................................................... 44 
Figure 3.11 : Morphological analysis of hippocampal neurons. Morphological 
analysis of hippocampal neurons after PMA and Gö6976 treatments. 
Analysis was performed by using Image-Pro Express (Meyer 
Instruments) software. (a) Hippocampal neurons were 
immunolabeled for neuron specific βIII tubulin. (b) Average total 
process lengths analysis of hippocampal neurons in control, PMA 
treated and 1 hour Gö6976 + 23 hours PMA treated conditions. (c) 
Average process number analysis of hippocampal neurons in control, 
PMA treated and 1 hour Gö6976 + 23 hours PMA treated conditions. 
Scale Bar, 47.02µm. Bar represents mean values ± SD. * p< 0.05. ...... 45 
Figure 3.12 : P-tau and p60-katanin protein levels in PMA treated hippocampal 
neurons. (a) Western bloting analysis of p-tau and p60-katanin 
protein lysates in control and PMA treated neurons. Control and 
PKC activated hippocampal neurons were immunolabeled for p-tau 
(Ser
199
) and p60-katanin proteins. (b) Quantitative analysis of the 
blots were achieved by normalizing band intensities of p-tau and 
p60-katanin against actin. Bar represents mean values ± SD. * p< 
0.05. ....................................................................................................... 46 
Figure 3.13 : GSK3β and p-GSK3β analysis in PMA treated hippocampal 
neurons. (a) Western blot analysis of GSK3β and p-GSK3β protein 
lysates in control and PMA treated neurons. Control and PKC 
activated hippocampal neurons were immunolabeled for GSK3β and 
p-GSK3β (Ser9). (b) Quantitative analysis of the blots were achieved 
by normalizing band intensities of GSK3β and p-GSK3β against 
actin. Bar represents mean values ± SD. ............................................... 47 
Figure 3.14 : Apoptosis and proliferation analysis of hippocampal neurons after 
PMA treatment. (a) Apoptosis and proliferation analysis of 
hippocampal neurons and mitotic cells. Cells were immunolabeled 
for cleaved PARP (blue, indication of apoptosis), phospho Histone3 
(green, indication of proliferation) and α-tubulin (red). (b, c) 
Western blot image of total protein lysate of control and PKC 
activated (PMA) hippocampal neurons. Lysates were separated with 
SDS-PAGE and probed with Bax, Bcl-2 (b), caspase3 (c) and actin 
(b, c) antibodies. .................................................................................... 48 
Figure 3.15 : Congo red staining of hippocampal neurons for Aβ plaques. Congo 
red staining was performed for hippocampal neurons following 24 
hours 7 µM Aβ treatment. Image was obtained by using light 
microscopy. Arrowheads show plaque depositions. ............................. 49 
Figure 3.16 : Immunofluorescence and Western blot analysis of PKC-α protein 
levels after Aβ and PMA treatments. Neurons were treated for 24 
hours with either 0.1% DMSO (control) or Aβ (amyloid) or neurons 
were pre-treated with Aβ for 24 hours and then PMA treated for an 
additional 24 hours (amyloid + PMA). (a) Cells were labeled with 
PKC-α (red), neuron specific βIII tubulin (green) antibodies and 
    
xxi 
 
DAPI (blue). (b) Western blot analysis of PKC-α (b,left) and 
quantitation of the blots (b, right). Bar represents mean values ± SD. . 50 
Figure 3.17 : Changes in relative mRNA levels of cell cycle proteins upon Aβ 
and PMA treatments. (a) Changes in relative mRNA levels of cell 
cycle proteins upon 24 h Aβ treatment and (b) 24 h Aβ treatment 
followed by 24 hours PMA treatment. Boxes represents the 
interquartile range of observations. The dotted line shows the median 
gene expression. Line represents  relative gene expression level for 
control cells which is accepted 1. Bar represents mean values ± 
SEM. * p< 0.05. .................................................................................... 52 
Figure 3.18 : Immunofluorescence analysis of cyclinD1 protein levels after Aβ 
and PMA treatments. (a) Neurons were treated for 24 hours with 
either 0.1% DMSO (control) or PMA or Aβ or neurons were pre-
treated with Aβ for 24 hours and then PMA treated for an additional 
24 hours (Aβ + PMA). Cells were labeled with cyclinD1 (cycD, red) 
and neuron specific βIII tubulin (green) antibodies. (b) Integrative 
pixel analysis as arbitrary fluorescence units (AFU) for 
immunofluorescence image of cyclinD1. Bar represents mean values 
± SD. * p< 0.05. .................................................................................... 53 
Figure 3.19 : Immunofluorescence analysis of pRb protein levels after Aβ and 
PMA treatments. (a) Neurons were treated for 24 hours with either 
0.1% DMSO (control) or PMA or Aβ or neurons were pre-treated 
with Aβ for 24 hours and then PMA treated for an additional 24 
hours (Aβ + PMA). Cells were labeled with pRb (red) and neuron 
specific βIII tubulin (green) antibodies. (b) Integrative pixel analysis 
as arbitrary fluorescence units (AFU) for immunofluorescence image 
of pRb. Bar represents mean values ± SD. * p< 0.05. .......................... 54 
Figure 3.20 : Morphological analysis of amyloid beta treated hippocampal 
neurons. (a) Hippocampal neurons were immunolabeled for neuron 
specific βIII tubulin. (b) Average total process lengths analysis of 
hippocampal neurons in control, PMA, Aβ, Aβ + PMA treated 
conditions. (c) Average process number analysis of hippocampal 
neurons in control, PMA, Aβ, Aβ + PMA treated conditions. Scale 
Bar, 47.02µm. Bar represents mean values ± SD. * p< 0.05. ............... 55 
Figure 3.21 : Western blot analysis of p-tau and p60-katanin protein levels after 
Aβ and PMA treatments. Neurons were treated for 24 hours with 
either 0.1% DMSO (control) or Aβ or neurons were pre-treated with 
Aβ for 24 hours and then PMA treated for an additional 24 hours 
(Aβ + PMA). (a, b) Western blot analysis and quantitation of the 
blots for p-tau (a) and p60-katanin (b). Bar represents mean values ± 
SD. ........................................................................................................ 56 
Figure 3.22 : Apoptosis and proliferation analysis of hippocampal neurons after 
Aβ treatment. (a) Apoptosis and proliferation analysis of neurons 
and mitotic cells. Cells were immunolabeled for cleaved PARP 
(blue), phosphor Histone3 (green) and α-tubulin (red). (b) Western 
blot image of total protein lysate of control, Aβ and sequencially 
amyloid teated and PKC activated (amyloid+PMA) hippocampal 
neurons. Lysates were probed with Bax, Bcl-2 and actin antibodies. 
(c) Quantitation of Western blot image in terms of Bax/Bcl2 ratio. 
Bar represents mean values ± SD. * p< 0.05. ....................................... 57 
    
xxii 
 
 
    
xxiii 
 
IDENTIFICATION EFFECTS OF PROTEIN KINASE C ACTIVATION IN 
NEURONS UNDER PHYSIOLOGICAL AND DEGENERATIVE 
CONDITIONS 
SUMMARY 
Neurons are highly differentiated cells and specialized for the processing and 
transmission of cellular signals. Neurons develop from mitotic cells of ectodermal 
origin and after several divisions, these cells begin to express neuron specific 
proteins and stop dividing early in development and hence, neurons direct their 
efforts of division towards the formation of axonal and dendritic processes, instead.  
Under normal circumstances, neurons are expected to reside in G0 phase of the cell 
cycle. However, recent studies showed that under neurodegenerative conditions such 
as Alzheimer’s disease (AD) – which is a progressive brain disorder and 
characterized by extracellular deposition of amyloid beta (Aβ) peptide, intracellular 
neurofibrillary tangles (NFTs) which primarily contain tau protein, and synaptic and 
neuronal loss – neurons basically leave G0, avoid G1/S checkpoint and continue to 
cell cycle, they even replicate their DNA. Why neurons bypass this checkpoint is still 
unknown. It has been found that some cyclins, like in cdk1-cyclinB1 complex, are 
re-activated in degenerating neurons of AD patients. Another reason that gives rise to 
cell cycle re-activation in Alzheimer’s neurons is increased activity of cyclinD1. Re-
activation of cyclinD1 results in activation of its partner cdk4 and Alzheimer’s 
neurons re-enter G1 phase of the cell cycle. However, there is evidence 
demonstrating that several of these cell cycle proteins in neurons can also play role in 
neuronal differentiation.  
Protein Kinase C (PKC) is a member of Ser/Thr protein kinase family. Activation of 
PKC generally depends on its targeting to the membrane compartments. Targeting to 
membrane compartments is promoted by second messengers such as diacylglycerol 
and arachidonic acid. However, there is also a growing body of evidence attributing 
nuclear functions for PKC such as DNA replication, RNA synthesis and processing, 
and gene expression. Hence, its precise subcellular distribution and roles especially 
in neurons are still unclear. 
Several alterations of many signal transduction pathways in AD have been reported 
and PKC is one of the proteins that have altered expression and activation levels in 
AD. PKC activity has been found to be altered in AD patients’ fibroblasts; altered 
activity and expression of particular PKC isoforms have also been demonstrated in 
postmortem brain cortex of AD subjects. Furthermore, amyloid beta has been shown 
to contain putative PKC pseudosubstrate domain and directly interact with PKC and 
alter its activity. PKC is also the upstream effector of many signaling pathways like 
Erk, GSK3β which have role in tau hyperphosphorylation where it is also associated 
with neurodegeneration. For instance, in AD neurons, tau dissociates from 
microtubules and form NFTs upon hyperphosphorylation via kinases like GSK3β. 
However, tau has also a key role in regulating microtubule dynamics, axonal 
transport and neurite outgrowth through site-specific phosphorylation events. For 
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instance p-tauSer199 is known to take a role in axonogenesis which is important for 
neuronal differentiation. 
Besides its role in signaling pathways which are associated with neurodegeneration, 
PKC has also been associated with proliferation and even differentiation. Expression 
of catalytically active PKC-α constructs was found to activate the expression of 
cyclinD1, via the AP-1 element of the cyclinD1 promoter, thus enhancing cell cycle 
progression. PKC-α activation can also promote cell cycle progression in glioma 
cells by up-regulating cyclinD1 and cyclin dependent kinase inhibitor, p21waf1/cip1. 
However, PKC-α can also play an inhibitory role during the regulation of the cell 
cycle through inactivation of cyclins. For instance, in crypt region of intestines, 
where differentiating, proliferating and stem cells are all present and where 
regulation of cell cycle arrest is strictly necessary, PKC activation resulted in cell 
cycle withdrawal into G0 phase due to a PKC-α mediated down regulation of 
cyclinD1 and increased expression of p21waf1/cip1 and p27kip1, which targets the 
inhibition of CDK complex activity. Therefore, PKC-α, has the ability to act as a 
growth stimulator or inhibitor depending on the cell system. When it comes to its 
role in differentiation, Western blot analysis of nuclei isolated from fully 
differentiated rat pheochromocytoma (PC12) cells demonstrated an increase in PKC-
α levels, which indicated a role for nuclear PKC-α in neuronal differentiation. 
The purpose of this study was to investigate the effects of PKC activation by Phorbol 
12-myristate 13-acetate (PMA), a general PKC activator, on cell cycle re-activation 
in neurons under non-degenerative (in physiological) and degenerative (Aβ treated) 
conditions. Quantitative Real Time Polymerase Chain Reaction (qRT-PCR), 
immunofluorescence and Western blotting analysis was performed to reveal 
expressional changes and distribution of PKC-α and cyclins in primary hippocampal 
neurons based on implications of cell cycle re-activation and PKC’s involvement in 
neurodegeneration. Furthermore, to reveal downstream effects of PMA directed PKC 
activation in neurons in terms of differentiation or de-differentiation, pRb and ppRb 
protein levels were also analyzed in order to understand how PKC activation would 
affect them in the pendulum of proliferation and differentiation in control and Aβ 
treated neurons. Since differentiation and de-differentiation states in neurons would 
be related to re-organization of cytoskeletal structure, microtubule structures in 
neuronal processes in PMA treated neurons were also analyzed. Changes in hyper-
phosphorylated tau and p60-katanin protein levels were also analyzed, since they are 
important players of microtubule stability and hence, crucial factors in neuronal 
branching. Finally, knowing that there are studies demonstrating up-regulation of cell 
cycle proteins like cyclinD1 in nucleus causing neurodegeneration; PMA and 
amyloid beta treated neurons were further analyzed for any potential activation of 
apoptosis or changes in proliferation.  
Results in this study showed that PMA mediated PKC activation elevates nuclear 
PKC-α and cyclinD1. These increases are accompanied by an increase in 
phosphorylation of pRb. Furthermore, PMA mediated PKC activation caused shorter 
process lengths and an increase in process numbers together with elevated p-tau and 
p60-katanin levels in hippocampal neurons which may indicate impairment from 
differentiation. However, in Aβ treated neurons (degenerative condition) there was 
no significant change observed in mRNA levels of cyclins; yet, cyclinA and cyclinB 
protein levels were elevated according to immunofluorescence analysis. pRb, p-tau, 
p60-katanin and p-GSK3β protein levels were also similar with control groups. 
Although there was no indication for apoptosis in any of the experimental conditions 
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in terms of cleaved PARP, there was an inclease in Bax/Bcl-2 ratio in Aβ conditions. 
However, in only PMA treated neurons Bax/Bcl-2 ratio was found to decrease.  
In conclusion, in addition to its previously known roles in cell cycle regulation, 
nuclear PKC may have effects causing withdrawal from differentiation in neurons by 
increasing nuclear cyclinD1 and promoting microtubule re-organization. 
Furthermore, Aβ seems to be obstacle for this designated role of PKC. 
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NÖRONLARDA FİZYOLOJİK VE DEJENERATİF KOŞULLAR ALTINDA 
PROTEİN KİNAZ C AKTİVASYONUNUN ETKİLERİNİN 
ARAŞTIRILMASI 
ÖZET 
Nöronlar ileri derecede farklılaşmış, sinyal iletimi ve sinyal işleme üzerine 
özelleşmiş hücrelerdir. Bu hücreler ektoderm kökenli mitotik hücrelerden gelişirler 
ve hayatlarının ilk evrelerinde bölünme özelliğine sahiptirler. Gelişimlerinin erken 
evrelerinde ise nörona özgü proteinler eksprese etmeye başlayarak bölünme 
yeteneklerini kaybederler; enerjilerini bölünmek yerine akson, dendrit gibi nöronal 
uzantılar oluşturmada kullanırlar.  
Normal koşullar altında nöronların hücre fazının G0 evresinde kalmaları beklenir. 
Ancak, hücre dışı amiloid beta (Aβ) plakları, tau proteininden oluşan hücre içi NFT 
ve nihayetinde sinaptik ve nöronal kayıplarla karakterize Alzheimer hastalığı (AH) 
gibi nörodejeneratif durumlarda nöronların G0 evresini terk ettiği, G1/S kontrol 
noktasını atlayarak hücre siklusuna devam ettiği, hatta DNA’sını replike ettiği 
gösterilmiştir. Nöronların bu kontrol noktasını neden atladığı tam olarak 
bilinmemektedir. Bununla beraber, Alzheimer hastalarının nöronlarında cdk1-
siklinB1 kompleksi gibi bazı siklinlerin tekrardan aktive edildiği bulunmuştur. 
Alzheimer nöronlarında hücre siklusun yeniden akivasyonunda etken olan başka bir 
sebep ise artan siklinD1 aktivitesidir. SiklinD1’deki aktivite artışı beraberinde 
partneri cdk4’ün aktivitesini de arttırır. Bundan dolayı da Alzheimer nöronları hücre 
siklusunun G0 fazını terk ederek tekrardan G1 fazına girebilir. Bununla birlikte, 
nöronlarda var olan hücre siklus proteinlerinin nöronal farklılaşmada görevleri 
olduğuna dair de bulgular mevcuttur.  
Protein Kinaz C (PKC) Ser/Thr protein kinaz ailesinin üyesi olup aktivasyonu 
genellikle bu proteinin hücrenin membran kompartmanlarına lokalizasyonu ile 
sağlanır. PKC’nin membran kompartmanlarına lokalizasyonu ise diaçilgliserol, 
araşidonik asit gibi ikincil mesajcı sinyal moleküllerince tetiklenir. Bununla birlikte, 
PKC’ye DNA replikasyonu, RNA sentezi ve işlemesi, gen ekspresyonu gibi 
nükleusta meydana gelen olaylarda görevler atfeden bulgular ve görüşler de 
artmaktadır. Kısacası PKC’nin hücre içi konumu ve görevleri özellikle nöronlar için 
henüz net olarak tanımlanamamıştır.  
AH’nda sinyal iletim yolaklarının birçoğu değişime uğramaktadır. PKC de AH’nda 
ekspresyon ve aktivasyon düzeyleri değişime uğrayan proteinler arasında yer 
almaktadır. Örneğin Alzheimer hastalarının fibroblast hücrelerinde PKC’nin 
aktivasyonunda değişimler olduğu görülmektedir. Benzer şekilde, AH sebebiyle 
yaşamını kaybedenlerin beyin korteks dokuları incelendiğinde belirli PKC 
izoformlarının hem aktivitesinde hem de ekspresyonun seviyesinde farklılıklar 
olduğu gösterilmiştir. Buna ilaveten, amiloid beta’nın PKC ile etkileşimi sağlayan 
substrat bağlanma bölgesi içerdiği, böylelikle de doğrudan PKC’nin aktivitesini 
etkileyebildiği gösterilmiştir. PKC, ayrıca tau proteininin aşırı fosforlanmasında 
görevli olan Erk, GSK3β gibi yolakların öncesinde yer alması bakımından da 
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önemlidir. Bilindiği gibi tau aşırı fosforlanması nörodejenerasyonla ilişkilidir. 
Fosforlanmamış halde mikrotubuller üzerinde tutunmuş halde bulunan tau proteini, 
Alzheimer nöronlarında da olduğu üzere, GSK3β gibi kinazlarca aşırı fosforlanmayı 
mütakiben mikrotubullerden ayrılır ve NFT (Neuro-Fibrillary Tangle) oluşturur. 
Nörodejenerasyondaki rolünden farklı olarak tau proteininin, fosforilasyon 
mekanizmasının da yardımıyla, mikrotubul dinamiklerini düzenlemede ve nörit 
uzamasını sağlamada da kilit görevleri bulunmaktadır. Örneğin Ser199’tan 
fosforlanan tau nöronal farklılaşmada da son derece önemli bir olay olan 
aksonogenezde görevlidir.  
PKC, nörodejenerasyon ile ilişkili yolaklardaki görevinin yanı sıra, hücre bölünmesi 
ve hatta hücre farklılaşması gibi olaylar ile de ilişkilendirilmektedir. Katalitik olarak 
aktif PKC-α konstrakları eksprese edildiğinde, siklinD1’in espresyonu dolayısı ile 
hücre siklusunun da aktive edildiği bulunmuştur. Benzer şekilde, gliyoma 
hücrelerinde de PKC-α, siklinD1 ve siklin bağımlı kinaz inhibitör (p21waf1/cip1) 
miktarını arttırmak suretiyle hücre siklusunda ilerlemeye sebep olmaktadır. Bu 
görevlerine ilaveten, PKC-α’nın siklinleri inaktive etmek suretiyle hücre siklusunun 
düzenlenmede negatif bir rolü de mevcuttur. Örneğin barsak kriptlerinde, ki bu 
bölgede bölünen, farklılaşan ve de kök hücrelerin tamamı mevcuttur, ve hücre siklus 
kontrolü çok sıkı gerçekleştirilir, PKC aktivasyonunun hücreleri G0 fazına çekilmeye 
tetiklediği gösterilmiştir. Bunun sebebi olarak da siklinD1’in PKC-α kaynaklı negatif 
regülasyonu, p21waf1/cip1 ve p27kip1’in ise artışı gösterilmektedir. Kısacası, PKC-
α, hücre bölünmesinde, hücre sistemine göre pozitif ya da negatif regülatör olarak 
görev yapabilmektedir. Diğer yandan PKC-α’nın hücre farklılaşmasındaki görevine 
örnek olarak ise PC12 hücreleri ile yapılan bir çalışma gösterilebilir. Bu çalışmada 
tamamen farklılaşması sağlanan PC12 hücrelerinin nükleusları izole edilmiş ve 
Western blotlama yöntemi ile PKC-α düzeyleri araştırılmıştır. Sonuçlar farklılaşma 
ile birlikte PKC-α düzeylerinde artışa işaret etmiştir.  
Tüm bu veriler ışığında, bu çalışmanın amacı nöronlarda fizyolojik ve dejeneratif 
koşullar altında Phorbol 12-myristate 13-acetate (PMA) kaynaklı PKC 
aktivasyonunu etkilerini nöronlarda hem dejeneratif (amiloid kaynaklı) hem de 
dejeneratif olmayan (fizyolojik) koşullar altında araştırmaktır. Bu amaca yönelik 
olarak gerçek zamanlı kantitatif PCR (qRT-PCR), immünflöresan boyama ve 
Western blotlama yöntemleri kullanılarak PKC-α ve siklinlerin ekspresyon düzey ve 
protein lokalizasyon farklılıkları bu iki farklı koşul altında primer hipokampal nöron 
hücreleri kullanılarak araştırılmıştır. Buna ilaveten, nöronlarda PMA kaynaklı PKC 
aktivasyonunun farklılaşma ya da geri-farklılaşma bakımından etkilerini araştırmak 
adına pRb ve ppRb protein düzeyleri de araştırılmıştır. Nöronlarda meydana gelen 
farklılaşma ya da geri-farklılaşma süreçleri sitoiskelet yapısının yeniden 
organizasyonu ile ilişkili olduğundan, PMA ile muamele edilen nöronlarda 
mikrotubul yapıları da detaylı incelenmiştir. Ayrıca, mikrotubul bütünlüğünü 
sağlamada ve nöronal dallanmanın oluşumunda önemli oyunculardan olan p-tau ve 
p60-katanin protein düzeylerindeki değişimler de PMA muamelesini mütakiben 
tesbit edilmiştir. Son olarak, siklinD1 gibi hücre siklus proteinlerinin artışını 
nörodejenerasyonla ilişkilendiren çalışmalar mevcut olduğundan, yaptığımız 
muamemelerin olası apoptoz ya da proliferasyon yolağı tetiklemesine sebep olup 
olmadığı araştırılmıştır.  
Sonuçlar PMA kaynaklı PKC aktivasyonunun nükleer PKC-α ve siklinD1 
seviyelerinde artışa sebep olduğunu göstermiştir. Bu artışa pRb’nin 
fosforilasyonundaki artış eşlik etmiştir. Dahası, PMA kaynaklı PKC aktivasyonu 
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nöronlarda daha kısa uzantıların oluşumuna yol açarken uzantı sayılarında, p-tau ve 
p60-katanin düzeylerinde de artışa sebep olmuştur, ki tüm bu veriler nöronlardaki 
farklılaşmada bir bozulmaya işaret etmektedir. Bununla birlikte, Aβ muamelesi 
içeren koşullarda siklin mRNA düzeylerinde anlamlı farklılıklara rastlanmamıştır. 
İmmünfloresan boyamalara istinaden sadece siklinA ve siklinB protein düzeylerinde 
artış görülmüştür. Çeşitli deneysel muamelelere tabi tutulan nöronlardaki pRb, p-tau, 
p60-katanin ve p-GSK3β protein düzeyleri de kontrol nöronları ile benzerlik 
göstermektedir. Deneysel grupların hiçbiri kesilmiş PARP bakımından analiz 
edildiğinde apoptoza işaret etmemektedir; ancak hücreler Bax/Bcl-2 oranı 
bakımından incelendiğinde Aβ muamelesi içeren koşullarda bu oranın arttığı 
gözlemlenmiştir. Halbuki sadece PMA ile muamele edilen nöronlarda Bax/Bcl-2 
oranı düşüş göstermektedir.  
Sonuç olarak, bu çalışma ile, hücre siklusuyla ilişkili hali hazırda bilinen görevlerine 
ilaveten nükleer PKC’nin nöronlarda nükleer siklinD1 artışı ve mikrotubullerin 
yeniden organizasyonu yardımı ile farklılaşmada gerilemeye yol açabileceği 
gösterilmiştir. Ancak, Aβ mevcut deney şartlarında nörodejenerasyonu tamamen 
tetiklememiş olsa da, PKC’nin kendisine atfedilen bu görevi yerine getirebilmesinde 
engeldir. 
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1.  INTRODUCTION 
1.1 Neurons 
Neurons are the primary cells of the nervous system. They develop from ectodermal 
origin mitotic cells. Although early in development neurons have ability to divide, 
after several divisions, they begin to express neuron specific proteins, stop dividing 
and become highly specialized for the processing and transmission of cellular signals 
(Figure 1.1) (Baas, 1999; Galderisi, 2003).   
 
Figure 1.1 : Simplified model of a neural stem cell. (Galderisi, 2003) 
Typical neuron has an enlarged cell body that contains a nucleus and most of the 
cytoplasmic organelles (Figure 1.1). Cell body is also the place where all the 
neuronal proteins are synthesized.  
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Figure 1.2 : Microtubule orientation in a typical neuron. (Lodish, 2003) 
Since neurons stop dividing, they direct their efforts of division towards the 
formation of axonal and dendritic processes, instead. They contain one axon and 
multiple dendrites (Figure 1.2). Axon sends information over long distances, whereas 
dendrites act as receptors for incoming information. Neurons are the most polarized 
cells in nature and this event is supposed to be maintained by neuronal cytoskeleton, 
especially microtubules. Axons contain long microtubules and their plus ends are 
oriented away from the cell body and microtubule polarity is uniform; whereas 
microtubules in the dendrites are short and they have mixed polarity orientation 
(Figure 1.2) (Baas, 1989; 1999; 2002). 
1.1.1 Cell cycle markers in mitotic cells and in neurons 
Eukaryotic cell cycle contains four main phases: G1, S, G2 and M phase (Figure 1.3). 
During G1 phase (first gap), mitogenic signals trigger synthesis of D-type cylins. 
These cyclins are partners of cdk4 or cdk6, and they together phosphorylate 
retinoblastoma protein (pRb). In late G1, cyclinE-cdk2 activity increases and 
completes pRb phosphorylation. From then on, cells are irreversibly committed to 
enter division process. When cells are in S phase (DNA sythesis), increased cyclinA-
cdk2 activity enables DNA replication and cells enter G2 phase (second gap). Then 
cyclinA-cdk1 regulates G2 and M phase cycle proteins together with cyclinB-cdk1. 
CyclinB-cdk1 complex has a role in late G2 and G2/M transition. Finally, in M phase 
(mitosis), cells divide and form two daughter cells (Currais, 2009).  
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Figure 1.3 : Schematic representation of the eukaryotic cell cycle. (Currais, 2009) 
There are two important checkpoints that control whether order and time of the cell 
cycle transitions are correct or not, G1/S and G2/M. These checkpoints ensure that 
DNA is already replicated and chromosomes are correctly segregated, and cell can 
decide between going through the cell cycle and arresting the cell growth or inducing 
apoptosis (Currais, 2009; Arendt, 2003). Under normal physiological circumstances, 
neurons are expected to reside in G0 phase of the cell cycle (Figure 1.3) by down 
regulating their mitotic proteins. 
1.1.1.1 Cell cycle markers in neurodegeneration  
Although neurons are expected to reside in G0 phase of the cell cycle, recent studies 
showed that in neurodegenerative diseases such as Alzheimer’s disease (AD), 
neurons exit G0, bypass G1/S checkpoint and continue cell cycle, and they even 
replicate their DNA (Figure 1.4) (Nagy, 2007; Yang, 2001).  
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Figure 1.4 : FISH applied to AD brain neurons for chromosome 11. Confocal image 
of a hippocampal neuron from an AD brain. Arrows indicate the 
presence of four bright spots of fluorescence in the nuclei, suggesting a 
doubling of the number of chromosomes 11 in this cell. (Yang 2001) 
Neurons down regulate their mitotic proteins under normal conditions. However, in 
degenerating neurons of AD patients, it has been found that cdk1-cyclinB1 complex 
was re-activated. Ordinarily, cdks are inactivated by cdk- inhibitors through the 
progression of the cell cycle and then reactivated when needed. However, similar as 
cyclin abnormalities, cdk-inhibitors are in their inactive state in neurons of AD 
patients. Hence, although required for neurons, in this case, cdks will not be able to 
be down regulated through the cell cycle as it would normally occur in otherwise  
healthy neurons (Nagy, 2007).  
Another reason that gives rise to cell cycle reactivation in Alzheimer’s neurons is 
increased activity of cyclinD1. Reactivation of cyclinD1 results in activation of its 
partner cdk4, and then neurons in AD re-enter G1 phase of the cell cycle (Nagy, 
2007). 
1.1.1.2 Cell cycle markers in differentiation 
Although most of the studies attribute neurodegenerative effects for cell cycle related 
proteins in neurons, recent evidence from different groups demonstrates the 
constitutive expression of cdks and cyclins indicating that expression of these 
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proteins might be correlated with differentiation (Schmetsdorf, 2005; Schmetsdorf, 
2007; Schwartz, 2007; Matsunaga, 2000; De Falco, 2004). As already indicated, 
terminally differentiated neural cells are arrested in the G0 phase and some key cell 
cycle regulatory proteins are down-regulated. However, cyclinD1, has been found to 
increase in some neural differentiation models (Hayes, 1991; Okano, 1993; Yan and 
Ziff, 1995; van Grunsven, 1996). In vivo analysis of cyclinD1 showed that reduced 
cyclinD1 expression correlates with neural development delay induced by nutritional 
deprivation (Tamaru, 1993; Tamaru, 1994; Shambaugh, 1996). Similarly, disruption 
of the cyclinD1 gene in mice revealed neurological defects (Sicinski, 1995). Yan and 
Ziff (1995) demonstrated that cyclinD1 was highly increased by inducers of 
differentiation, such as NGF and FGF, and not by inducers of proliferation (EGF and 
insulin) in PC12 cells. In agreement with those, Xiong et al. (1997) have found that 
bFGF treatment caused 10-fold increase in cyclinD1 protein that was localized 
primarily in nucleus (Xiong, 1997). However, none of the above studies were able to 
explain the reason of increase in cyclinD1 during neuronal differentiation.  
Furthermore, Schmetsdorf et al. (2009) showed that cell cycle related proteins 
interact with microtbule network in neurons. They also showed that these proteins 
have tau phosphorylation ability and have roles in neurite outgrowth regulation. 
According to these results, cell cycle related proteins are attributed dual functions: 
proliferation control in mitotic cells and structural plasticity control in post-mitotic 
neurons. 
1.1.2 Amyloid beta in physiological neurons 
AD is a progressive brain disorder characterized by intracellular neurofibrillary 
tangles (NFTs) which contain primarily tau protein, extracellular deposition of 
amyloid beta (Aβ) peptide, and synaptic and neuronal loss (Iwata, 2005). How Aβ 
contributes to development of AD is not exactly defined and studies mostly have 
focused on the neurotoxic effetc of Aβ, but physiological roles of Aβ were relatively 
less defined. There are some cellular functions attributed to Aβ. 
Aβ is produced by sequential proteolysis of the amyloid precursor protein (APP) (De 
Strooper, 2000; Haass, 2005) and production and subsequent release of Aβ positively 
correlate with the level of neuronal and synaptic activity (Kamenetz, 2003; Cirrito, 
2005) and consistent with this, recent study that was published in 2009 by Abramov 
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et.al, indicated that both elevation and reduction in Aβ levels attenuated short-term 
synaptic facilitation during bursts in excitatory synaptic connections and suggested a 
role for endogenous Aβ in the regulation of synaptic vesicle release and concluded 
that this role of Aβ might be associated with the pathological events that lead to 
synapse loss in Alzheimer’s disease. 
In another study (Morley, 2010) low doses of Aβ  were applied in the hippocampus 
in vivo and memory retention and enhanced acetylecholine production were 
enhanced in two tasks. Same study has tested whether endogenous Aβ had a role in 
learning and memory in young. For this purpose they blocked endogenous Aβ in 
healthy 2-month-old cognitively intact mice. Results indicated impaired learning in 
T-maze foot-shock avoidance. They also revealed that Aβ(1-42) facilitated induction 
and maintenance of long term potentiation (LTP) in hippocampal slices, whereas 
antibodies to Aβ inhibited hippocampal LTP. In conclusion, this study indicated that 
Aβ is important for learning and memory in normal healthy young animals. 
1.1.2.1 Amyloid beta and PKC interaction  
In addition to these functions attributed to Aβ, another role of Aβ might be through 
Protein Kinase C (PKC) signaling, since Aβ was found to contain a putative PKC 
pseudosubstrate site in Aβ(28-30) (KGA) which is responsible for direct Aβ – PKC 
interaction (Chauhan, 1991; Lee, 2004). There are two proposed model for this 
interaction as illustrated in Figure 1.5. According to the first model, very similar to 
PS motif, Aβ binding changes conformation of PKC and keeps protein in its inactive 
state. According to the second model, Aβ bind to C4 domain of PKC and prevents 
the binding of PKC substrates. The exact binding mechanism of PKC -  Aβ is still 
unclear. 
There are several alterations observed in PKC signaling pathways in AD cases. For 
instance, PKC activity has been consistently found to be reduced in AD fibroblasts, 
decreased PKC activity and translocation have also been demonstrated in the brain of 
AD patiens (Lee, 2004; Gasparini, 1998). Furthermore, Aβ has been shown to 
degrade PKC-α in normal human fibroblasts and PKC-γ in AD patient fibroblasts 
(Favit, 1998); to reduce PKC-mediated phosphorylation of several soluble brain 
proteins in a liposome system (Chauhan, 1991) and moreover, to induce translocation 
of PKC from membrane fraction to cytosol in cultured brain endothelial cells 
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(Pakaski, 2002). All these studies address an inhibitory role for Aβ on PKC activity 
besides its role in contributing to the progress of AD.  
 
Figure 1.5 : Illustration of PKC – Amyloid interaction. 
1.2 Protein Kinase C (PKC) Protein Family 
Protein Kinase C (PKC) is a member of Ser/Thr family of phosphorylating enzymes 
and it was originally discovered in 1977 as a histone protein kinase activated by 
calcium and diacylglycerol (DAG), phospholipids, and/or phorbol esters (Takai, 
1977). These kinases have roles in wide range of cellular events such as ion flux, 
receptor modulation, cell proliferation, synaptic re-modelling, gene expression, etc. 
(Figure 1.6).  
 
Figure 1.6 : PKC translocation dependent pathways. (Amadio, 2006) 
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At least 10 PKC isoforms have been described based on sequence homology and 
activator sensitivity, and these isoforms are clasified in three classes (Figure 1.7): 
The first class is calcium-dependent or conventional cPKCs (α, βI, βII, γ); the second 
class is calcium-independent or novel nPKCs (δ, ε, μ, η, θ); and finally the third class 
is atypical aPKCs (ζ, λ, ι) (Amadio, 2006; Newton, 2003; Nishizuka, 2001; Giorgi, 
2010). 
 
Figure 1.7 : Classification and structure of PKC isoforms. (Giorgi, 2010) 
PKC polypeptide consists of a C-terminal catalytic domain and an N-terminal 
regulatory domain (Figure 1.7). cPKCs have four conserved domains: C1, C2, C3 
and C4, and these domains are separated by regions composed of variable sequences 
V1, V2, V3, V4 and V5. Specific PKC activators interact with the enzyme via 
regulatory domains (Amadio, 2006; Giorgi, 2010). The C1 domain is composed of 
one or two cysteine-rich domains which also serve as docking sites for PKC 
activators such as physiological activator DAG and its analog phorbol esters (such as 
PMA). The C2 domain contains Ca
+2 
binding site and it is present in both cPKC and 
nPKC. C1 domain is a putative membrane binding domain (Giorgione, 2006). 
Finally, C3 contains the ATP binding region, while C4 bears the substrate docking 
sequence (Newton, 1998). There is a pseudosubstrate (PS) or autoinhibitory region 
localized close to the C1, and this region keeps PKC in an inactive form (Figure 1.8). 
Upon interaction with its specific activators, folded conformation of PKC is opened. 
These activators decrease the affinity of autoinhibitory domain for the catalytic site, 
and hence, PKC becomes active. Activation of PKC can be described as a shift in the 
equilibrium between two states of the catalytic domain; PS-bound and PS-unbound 
(Kraft, 1983; Giorgi, 2010). Ca
+2
 and DAG can sequentially activate cPKC. Ca
+2
 acts 
rapidly but the binding of DAG to the active site of PKC is initially prevented by PS 
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and delays kinase activation (Oancea, 1998). Upon DAG binding to the regulatory 
domain of PKC, PKC increases its affinity for membrane lipids and tranlocates to the 
plasma membrane. Other lipids such as arachidonic acid, phosphatidylinositol (PI) 
4,5-bisphosphate, and phosphatidylinositol 3,4,5-trisphosphate (PIP3) can also 
stimulate PKC activity. Phorbol esters such as PMA, mimic DAG by binding to the 
same site in the regulatory domain (Giorgi, 2010). Whenever PKC translocates to the 
plasma membrane of the cell, PS releases and PKC becomes active (Figure 1.8). 
 
Figure 1.8 : Proposed activation model for PKC. (Medkova and Cho, 1999) 
1.2.1 Nuclear activities of PKC 
Most of the functions of PKC have been associated to events that occur within the 
membrane – cytoplasm compartments of the cells. However, there is a growing body 
of evidence indicating that PKC has functions in nuclear compartments of the cells 
such as DNA replication, RNA synthesis and processing, gene expression (Martelli, 
2006), and some studies link nuclear PKCs with cell proliferation as it was also 
observed in investigations on the laminin B, a nuclear envelope component and a 
major PKC substrate in HL60 cells (Hocevar, 1993). In the study by Hocevar et. al. 
(1993), following DAG-mimicking compound treatment, PKC-βII was found to 
translocate to the nucleus and phosphorylate laminin B. This phosphorylation leads 
to laminin disassembly and entry into mitosis. There are some other substrates for 
nuclear PKCs identified over the years. These proteins are: histone (H1, H2B, H3), 
lamins (A/C), DNA topoisomerase I and IIα, DNA polymerase β, DNA 
methyltransferase, etc ... (Martelli, 2006; Omri, 1987; Ajiro, 2000; Huang, 2004; 
Haas, 1993; Eggert, 1991; Pommier, 1990; Sahyoun, 1986; Tokui, 1991; DePaoli-
Roach, 1986). Nevertheless, these findings are still unclear, since investigators 
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cannot surely decide whether or not PKC-dependent phosphorylation of some of 
these substrates takes place within the nucleus or elsewhere in the cell. 
Similar to situation in cell proliferation, there is a body of evidence that suggests role 
in differentiation regulation for nuclear PKC isoforms, especially in 
hematolymphopoietic cell line (Martelli, 1999). Although there is a lack of functional 
studies that would clarify the issue of how nuclear PKC may influence 
differentiation, there are speculations that PKC, once in the nucleus, may influence 
transcription of the genes essential for cell differentiation.  
Although information in the field of nuclear PKCs is accumulating in the literature, 
more detailed studies are still needed to be designed in order to better understand the 
mechanism of phosphorylation events by PKCs that take place in the nucleus. 
1.2.2 PKC-α 
Mammalian PKC-α is composed of 672 amino acids and is distributed throughout all 
tissue types. It is activated by a variety of stimuli such as guanine-nucleotide-binding 
protein-coupled receptor signaling, tyrosine kinase receptor signaling (Nishizuka, 
1992; Dempsey, 2000; Newton, 2001; Nishizuka, 1995; Parekh, 2000), physical 
stress like hypoxia (Lo, 2001) and mechanical stress (Cheng, 2001). Hence, PKC-α 
isotype has important functions in various cellular events such as proliferation, 
apoptosis, differentiation, motility and so on (Figure 1.9). 
 
Figure 1.9 : Possible interactions of PKC-α with other signaling pathways. (Michie 
and Nakagawa, 2005) 
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Depending on its activation time and activation type, the substrate that takes role in 
activation, response of PKC-α can vary. However, complete lists of these cell – 
specific factors are still unavailable (Nakashima, 2002). 
1.2.2.1 PKC-α regulation 
PKC-α is regulated in the cell by three mechanisms: phosphorylation, co-factor 
binding and intracellular localization (Parekh, 2000; Newton, 2001).  
A. Phosphorylation 
PKC-α has to be serially phosphorylated to attain its active form. There are three 
proposed phosphorylation sites localized in catalytic domain of PKC-α (Figure 1.10); 
Thr497 (in the activation loop), Thr638 (in the turn motif) and Ser657 (in the C-
terminal motif) (Parekh, 2000). Phosphorylation of Thr497 is independent from 
internal PKC-α activity and was shown to be prerequisite to full phosphorylation of 
PKC-α and subsequent activation; however, phosphorylation of Thr638 and Ser657 
are autophosphorylation-mediated and promoted by Thr497 phosphorylation (Pears, 
1992; Cazaubon, 1993; Cazaubon, 1994). 
 
Figure 1.10 : Phosphorylation sites of PKC-α. (Michie and Nakagawa, 2005) 
B. Co-factor binding 
Phosphorylated PKC-α resides in the cytoplasm and requires additional regulatory 
mechanisms to be fully active. As already mentioned, there is a PS domain in the N- 
terminal of PKC-α that prevents catalytic domain – substrate interaction, therefore 
phosphorylation of substrate (Nishizuka, 1995). Upon receptor – ligand binding, 
phosphatidylinositol-specific phospholipaseC (PLC) cleaves phosphatidylinositol-
4,5-bisphosphate (PIP2) into the calcium mobiliser, inositol-1,4,5-triphosphate (IP3) 
and DAG (Figure 1.8) (Nishizuka, 1995). Following serial activation events and co-
factor bindings to C1 and C2 domains, PKC-α binds to plasma membrane and 
changes its conformation, which also enables release of PS domain from substrate 
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binding site (Newton, 2001). Therefore, co-factor binding is especially important in 
plasma membrane localization and subsequent activation of PKC-α.  
1.2.3 Roles of PKC-α  
1.2.3.1 Roles of PKC-α in proliferation and differentiation 
Studies on the role of PKC-α showed that thymocyte cells isolated from transgenic 
mice over-expressesing wild-type PKC-α display higher proliferation rate upon 
stimulation compared to the response of control cells upon stimulation (Iwamoto, 
1992). Furthermore, studies with PKC-α MCF-7 breast cancer and malignant U87 
glioma cells confirmed increase in proliferation upon over-expression of PKC-α 
(Mandil, 2001; Ways, 1995). In contrast, there are studies that showed inhibition of 
proliferation by PKC-α. For instance, in IEC-18 intestinal crypt cells, PKC-α 
activation appeared to lead to cell cycle arrest by accumulation of the ppRb and 
induction of the cyclin-dependent kinase inhibitors (Frey, 2000). When it comes to 
differentiation, studies with T-cells demonstrated PKC-α mediated differentiation 
and proliferation of pre-T cells via ERKMAPK-and cyclic AMP response element 
binding protein mediated pathways (Grady, 2004; Michie, 2001). 
1.2.3.2 Roles of PKC-α in cell cycle regulation 
Studies on the role of PKC-α in cell cycle regulation demonstrated that expression of 
catalytically active PKC-α constructs enhance cell cycle progression by increasing 
cyclinD1 expression through AP-1 element of cyclinD1 promoter (Soh and 
Weinstein, 2003). PKC-α activation was also found to promote cell cycle progression 
in glioma cells by up-regulating cdk inhibitor p21waf1/cip1 (Besson and Yong, 
2000). However, PKC-α can also have inhibitory function in cell cycle regulation. In 
intestinal epithelial cells, PKC-α signaling results in cell cycle withdrawal into G0 
phase by down-regulation of cyclinD1 and up-regulation of cdk inhibitors 
p21waf1/cip1 and p27kip1 (Frey, 2000). Similary, in pancreatic cancer cells PKC-α 
signaling inhibited cell growth by arresting the cells in G1 phase through increased 
p21waf1/cip1 expression and hence inhibition of cdk2 and ppRb (Detjen, 2000). 
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1.3 Aim of the Study 
PKC is one of the proteins that have altered expression and activation levels in 
neurodegenerative disease, such as AD. Decreased activity and expression of 
particular PKC isoforms have been demonstrated in post-mortem brain cortex of AD 
patients. Furthermore, amyloid beta was found to directly interact with PKC and 
decrease its activity. PKC is also an upstream effector of signaling pathways such as 
Erk, GSK3β that have role in tau hyper-phosphorylation.  
In this content, the purpose of the thesis was to investigate the effects of PKC 
activation by PMA, a general PKC activator which mimics DAG, on cell cycle re-
activation in neurons under non-degenerative (in physiological) and degenerative 
(Aβ treated) conditions. Seeing differential effects of PKC-α in different mitotic cell 
types, PKC activation studies in neurons’ physiological condition would also provide 
information about the effects of PKC on cyclins in post-mitotic hippocampal neurons 
to gain insights into understanding the role of PKC-α in neurons. This study would 
provide an opportunity to observe discrepancies in PKC signaling pathway between 
physiological (non-degenerative) and Aβ treated (degenerative) neurons in terms of 
changes in protein level and distribution of cyclins and PKC-α itself. To reveal 
downstream effects of PMA mediated PKC activation in neurons in terms of 
differentiation or de-differentiation, changes in pRb and ppRb protein levels were 
also determined in order to understand how PKC activation would affect them in the 
pendulum of proliferation and differentiation in case of deviation of neurons from 
their normal physiological state upon PKC activation. Since differentiation and de-
differentiation states in neurons would be related to re-organization of cytoskeletal 
structure, microtubule structures were also analyzed in PMA treated neurons. Since 
they are important players of microtubule integrity and crucial factors in neuronal 
branching, changes in hyper-phosphorylated tau and p60-katanin protein levels were 
also analyzed. Finally, all experimental conditions were analyzed for any potential 
activation of apoptosis or changes in proliferation upon PKC activation. 
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2.  MATERIALS AND METHODS 
2.1 Materials 
2.1.1 Animals 
Post-natal 0 (PN0) Sprague-Dawley rats were used for hippocampal neuron 
culturing. All the animals were handled according to appropriate animal care and 
utilization procedures. Ethical approval was obtained from Marmara University, 
05/09/2008. The procedures involving experimentation on animal subjects were done 
in accordance with both the guidelines provided by the local authorities and the 
National Research Council's guidelines for the care and use of laboratory animals. 
2.1.2 Antibodies used in this study 
Primary antibodies used in this study are listed in Table 2.1. 
Table 2.1 : Primary antibodies. 
Antibody name Producer Catalog number 
Goat anti PKC-α Santa Cruz sc-208 
Rabbit anti cyclinD1 Santa Cruz sc-717 
Rabbit anti cyclinA Santa Cruz sc-596 
Rabbit anti cyclinB1 Santa Cruz sc-595 
Rabbit anti cyclinE Santa Cruz sc-198 
Mouse βIII tubulin Promega G-7121 
Mouse anti β-actin Santa Cruz sc-47778 
Rabbit anti Histone3 Cell Signaling 9715 
Goat anti phospho pRb Ser807/811 Santa Cruz sc-16670 
Rabbit anti pRb Santa Cruz sc-50 
Rabbit anti phospho tau Ser199 Invitrogen 44-734G 
Mouse anti p60-katanin Akkor & Karabay  
Rabbit anti phosphor GSK3β Ser9 Cell Signaling 9323 
Mouse anti GSK3β  Cell Signaling 9832 
Rabbit anti Bax Cell Signaling 2772 
Rabbit anti caspase 3 Cell Signaling 9665 
Rabbit anti Bcl-2 Cell Signaling 2870 
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Secondary antibodies used in this study are listed in Table 2.2. 
Table 2.2 : Secondary antibodies. 
Antibody name Producer Catalog number 
anti rabbit HRP Promega w401b 
Donkey anti goat HRP Promega v805a 
anti mouse HRP Promega w402b 
Alexa Fluor® 488 goat anti-mouse Invitrogen A11029 
Alexa Fluor® 647 goat anti-rabbit Invitrogen A21245 
2.1.3 Buffers and solutions 
2.1.3.1  Tris buffer saline 
10X stock solution of tris buffer saline (TBS) was prepared by dissolving 87.66 g 
NaCl and 12.1 g Tris in 1 lt ddH2O. pH was adjusted to 8.0. Working solution (1X 
TBS) was prepared by diluting 10X TBS by 10 times.  
2.1.3.2 Tris buffer saline – Tween20 
Tris buffer saline – Tween20 (TBS-T) was prepared by dissolving 0.1% (v/v) 
Tween20 in 1X TBS. TBS-T was used as washing buffer in Western blot 
experiments throughout the study. 
2.1.3.3 Towbin buffer 
Towbin buffer was prepared by dissolving 1.5 g (25 mM) Tris, 7.5g (192 mM) 
Glycine and 20% (v/v) Methanol in 500 mL ddH2O. Towbin was used as transfer 
buffer in Western blot experiments throughout the study. 
2.1.3.4 Immunofluorescence blocking buffer 
Blocking buffer application is important to reduce nonspecific antibody bindings. To 
prepare 1 mL blocking buffer 100 µl (10%) Goat (or Donkey, depending on the type 
of secondary antibody) serum and 10 mg (10 mg/mL) BSA were dissolved in 1X 
PBS and filtered with 0.8 µm Nalgene filter. This blocking buffer was used in 
immunofluorescence staining procedure throughout the study.  
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2.1.3.5 Western blotting blocking buffer 
To prepare 100 mL blocking buffer, 1 g (1%) BSA and 5 g (5%) skim milk were 
dissolved in 1X TBS. This blocking buffer was used in Western blotting procedure 
throughout the study. 
2.1.3.6 Western blotting stripping buffer 
To prepare 100 mL stripping buffer, 200 mM Glycine was dissolved in ddH2O and 
pH was adjusted to 2.5 with HCl. Prior to use 0.5% Tween20 was added into Glycine 
solution. This stripping buffer was used in Western blotting procedure for reprobing 
experiments throughout the study. 
2.1.3.7 PMA solution 
To prepare 100 µM stock PMA solution, 1mg PMA was dissolved in 16.2 mL 
DMSO. Working concentration was diluted in hippocampal serum free plating 
medium prior to treatment.  
2.1.3.8 Gö6976 solution 
To prepare 500 µM stock Gö6976 solution, 1mg Gö6976 was dissolved in 5.3 mL 
DMSO. Working concentration was diluted in hippocampal serum free plating 
medium prior to treatment. 
2.1.3.9  Amyloid beta (1-42) solution 
To prepare amyloid beta (1-42) (Aβ) peptide for neurotoxicity studies, peptide 
aggregation has to be induced since peptide is supplied in a non-neurotoxic form. 
Pre-incubation is required to obtain aggregated peptide structure. For this purpose; 
Lyophilized peptide was dissolved in HPLC grade water to obtain 6 mg / mL 
concentration. Peptide was diluted with Ca
2+
 free PBS to 1 mg / mL and incubated at 
1000 rpm 37°C for 24 hours. Neurotoxicity is usually observed at 30 - 100 µg / mL 
which correspond to ~ 6.5 – 22 µM.  
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2.1.4 Primary hippocampal neuron culture media 
2.1.4.1 Hippocampus dissection medium  
Hippocampus dissection medium was prepared with 10 ml 10X HBSS, 1 ml 1M 
HEPES and 1 ml Penicillin-Streptomycin (Pen/Strep). Final volume was brought to 
100 ml by addition of 88 ml ddH2O. Medium was filter sterilized with 0, 2 µm 
Nalgene filter.  
2.1.4.2 Hippocampal plating medium  
Hippocampal medium was prepared by dissolving 1 mL B27 Supplement, 0.33 mL 
45% D-Glucose, 0.25 mL L-Glutamine and 2.5 mL FBS in 45.92 mL Neurobasal 
medium. Medium was filter sterilized with 0.2 µm Nalgene filter. Hippocampal 
medium was used in wash steps during hippocampi dissection procedure. 
2.1.4.3 Hippocampal serum free plating medium 
Hippocampal serum free medium was prepared by dissolving 1 mL B27 Supplement, 
0.33 mL 45% D-Glucose and 0.25 mL L-Glutamine in 48.42 mL Neurobasal 
medium. Medium was filter sterilized with 0.2 µm Nalgene filter.  
2.1.5 Cell line media 
2.1.5.1 Mouse 3T3 fibroblast medium 
Fibroblast medium was prepared by dissolving 1 mL L-Glutamine (4mM), 5 mL 
FBS, 100 µl pen/Strep in 44 mL DMEM (low glucose). Medium was filter sterilized 
with 0.2 µm Nalgene filter. Medium was used during cultivation of 3T3 mouse 
fibroblast cells. 
2.1.5.2 SH-SY5Y neuroblastoma medium 
Neuroblastoma medium was prepared by dissolving 1 mL L-Glutamine (4mM), 10 
mL FBS, 200 µl pen/Strep in 89 mL DMEM (low glucose). Medium was filter 
sterilized with 0.2 µm Nalgene filter. Medium was used during cultivation of SH-
SY5Y neuroblastoma cells. 
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2.1.6 Chemicals 
Chemicals used in this study are listed in Table 2.3. 
Table 2.3 : Chemicals. 
Chemical  Producer 
B27 Gibco 
DNase Sigma 
2.5% Trypsin Invitrogen 
D-Glucose L-glutamine 
Poly-L-lysine Sigma 
HEPES Gibco 
HBSS Gibco 
FBS Gibco 
Penicillin / Streptomycin Sigma 
PMA Calbiochem 
Gö6976 Calbiochem 
DMSO Sigma 
Methanol Merck 
Mounting Medium Sigma 
BSA Sigma 
Skim milk Fluka 
SeeBlue® Plus2 Protein Ladder Invitrogen 
Goat Serum Gibco 
Donkey Serum Gibco 
Ethanol Merck 
Paraformaldehyde Sigma 
Triton X100 Sigma 
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2.1.7 Commercial kits 
Commercial kits used in this study are listed in Table 2.4. 
Table 2.4 : Commercial kits. 
Kit name Producer 
High Pure RNA Isolation Kit Roche 
Quant-iT™ RNA, BR Assay Kit Invitrogen 
RevertAid™ First Strand cDNA Synthesis Kit Fermentas 
LightCycler® 480 Probes Master Kit Roche 
NE-PER™ Nuclear and Cytoplasmic Protein Extraction Kit Pierce 
Mammalian Cell Extraction Kit Biovision 
BCA Protein Assay Kit Pierce 
SDS Gel Preparation Kit Fluka 
ECL plus HRP Detection Kit 
GE 
Healthcare 
SuperSignal® West Femto HRP Detection Kit Thermo  
2.1.8 Primer and probe sets used in quantitative real time PCR 
Primer and probe sets used in qRT-PCR in this study are listed in Table 2.5. Probes 
and primers were designed by using Roche Universal Probe Library software. Probes 
were purchased from Roche Universal Probe Library, and primers were purchased 
from Integrated DNA Technologies, Inc.  
Table 2.5 : Primer and probe sets. 
Gene name Accession number Primer sequence Probe number 
cyclinA NM_001011949.1 
gagagggaaattgcagcttg 
gggcgggtatatctcttcgt 
2 
cyclinB1 NM_171991.2 
tgtgaaagatatctatgcttacctcag 
cccagtaggtattttggtctaactg 
65 
cyclinD1 NM_171992.4 
gcacaacgcactttctttcc 
tccagaagggcttcaatctg 
16 
cyclinE NM_001100821.1 
ctgagagatgagcactttctgc 
tggagcttatagacttcacacacc 
108 
cdk1 NM_019296.1 
tcatggattcttcgctcgtt 
tcgggagtgacaaaacacaa 
65 
cdk2 NM_199501.1 
gcatctttgccgaaatggt 
gatccggaagagttggtcaat 
80 
cdk4 NM_053593.2 
gtcagtggtgccggagat 
ggattaaaggtcagcatttcca 
50 
p27 NM_031762.3 
agacagtccggctgggtta 
ttctgttctgttggcccttt 
130 
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2.1.9 Gene assays used in quantitative real time PCR 
Gene assays that were used as internal controls for normalization of gene expression 
levels in qRT-PCR were purchased from Roche Universal Probe Library and are 
listed in Table 2.6. Gene assays are used as housekeeping for normalization of qRT-
PCR results throughout the study. 
Table 2.6 : Gene assays. 
Gene assay Catalog number 
Rat ACTB 05046203001 
Rat GAPD 05046220001 
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2.1.10 Laboratory equipment 
Laboratory equipment that were used in this study are listed in Table 2.7. 
Table 2.7 : Laboratory equipment. 
Laboratory equipment Producer 
Autoclave NüveOT 4060 Steam Sterilizer 
 -80˚C Heto Ultrafreeze 4410 
Deep freezers and refrigerators -20˚C Arçelik  
 +4˚C Arçelik 
Electrophoresis tank Midicell PrimoTM EC 330  
Fluorometer 
Qubit  
Invitrogen Q32857 
CO2 Incubator Shel Lab 
Laminar flow cabinet Faster BH-EN  
Light microscope Olympus CH30  
Microfuge Beckman
®
 Coulter Microfuge  
Centrifuge Eppendorf Centrifuge 5424 
Micropipettes 
Eppendorf 2.5 μl 10 μl, 20 μl, 200 μl, 
1000 μl 
pH meter Mettler Toledo MP220  
Power supply  BioRad 
Real time PCR LightCycler 480 II Roche  
Thermomixer Eppendorf  
Ultrapure water system TKA Wasseraufbereitungssysteme 
Water baths Memmert 
Hemacytometer Fisher Scientific 
Filters  Nalgene  
Confocal microscope Leica, TCS SP2 SE 
Dissection microscope Olympus 
Spectrophotometer  PerkinElmer Lambda25 UV/VIS  
Densitometer BioRad 
Semi-dry blot system BioRad 
Dumont-style forceps (no:5) EMS 
Plastic culture dishes TPP 
Falcon tubes BD 
2.2 Methods  
2.2.1 Primary hippocampal neuron culture 
When the cultures started from cells, tissues or organs taken directly from organisms, 
it is named “primary culture”. Upon dissociated and plated into culture dish, neurons 
that have completed their division in situ start to extend processes, form synapses 
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with one another, etc. Neurons also retain their individual identities in culture dish 
and each different type of neurons expresses its own properties.  
2.2.1.1 Dissection of the hippocampus 
To obtain dissociated primary neuron culture from hippocampi, first hippocampi 
from PN0 Sprague – Dawley rat brains were dissected. Hippocampus disection 
procedure is indicated below: 
 PN0 rats were transferred on ice bucket to obtain anaesthesia. To minimize any 
contamination risk, rats were briefly rinsed in 70% ethanol prior to dissection 
procedure. 
 Heads were transferred to a culture dish containing hippocampus dissection 
medium pre-warmed to 37°C. 
 Brains were removed under a dissection microscope. For this procedure Dumont-
style forceps (no:5) were used.  
o The cerebral hemispheres were separated from diencephalon and brain 
stem (Figure 2.1 A, B). Diencephalon and brain stem were discarded.  
o Meninges were carefully removed (Figure 2.1 C). 
o Figure 2.1 D shows one of the hemispheres after removal of meninges. 
Arrowheads indicate the boundary between the hippocampus and cortex; 
small arrows mark the free edge of the hippocampus.  
o Figure 2.1 E shows the removal of hippocampus. The hemisphere was 
stabilized with forceps and another forceps was used to cut the 
hippocampus and to take it out of the hemisphere.  
o Figure 2.1 F shows the hippocampus after it has been removed. 
 Following dissection, hippocampi were transfered to a dish containing 
hippocampus dissection medium. The hippocampi were cut into small pieces and 
transferred into 15 mL conical centrifuge tube. 
 The volume was brought to 4.5 mL with hippocampus dissection medium. 
 0.5 mL 2.5% Trypsin and 0.25 mL (10 mg/ mL) DNase were added into the tube. 
Tube was gently mixed and incubated in 37°C water bath for 35 minutes. 
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 Hippocampi pieces were settled to the bottom of the tube. At the end of 
incubation step, trypsin and DNase were pipetted off. 
 Hippocampi pieces were rinsed 2 times for 5 minutes each with 5 mL 
hippocampal plating medium. 
 Finally 1 mL of warm (37°C) hippocampal plating medium was added into the 
tube.  
 Trituration was performed 6 – 7 times against the side of the tube with a fire-
polished Pasteur pipette. The medium was especially pushed out against the side 
of the tube to prevent frothing since the cells at the air-liquid interface can be 
lysed.  
 Dissociation was completed, and the cell density was determined by using 
hemacytometer. Neurons were plated onto 200 µg / mL poly-L-lysine coated 
culture dishes at a density of 1x10
6
 cells / 34 mm culture dish for RNA isolation 
experiments, and 2.5x10
6
 cells / 60 mm culture dish for Western blot 
experiments. For immunofluorescence analysis, neurons were plated onto 1 mg / 
mL poly-L-lysine coated 18 mm glass coverslips at a density of 3x10
4
 cells / 
coverslip. Cultures were maintained in 37°C, 5% CO2 environment. 
2.2.2 Cultivation of mouse 3T3 fibroblast or SH-SY5Y neuroblastoma cells 
3T3 fibroblast and SH-SY5Y neuroblastoma cell stocks were taken out from -80°C 
freezer. Tubes containing cell lines were shaken very carefully in 37°C waterbath 
and cells were transferred into 10 ml of 37°C warmed apropriate growth medium. 
Cells were centrifuged at 3000 rpm for 5 minutes. Supernatant was removed, 1 ml 
fresh 37°C warmed medium was added into the tube and the pellet was resuspended. 
Since these cells were used in immunofluorescence studies, they were plated on 
poly-L-lysine coated (for neuroblastoma cells) or non-coated (for fibroblasts) 
coverslips and maintained in 37°C, 5% CO2 environment.  
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Figure 2.1 : Hippocampus dissection. (Banker & Goslin, 1998) 
2.2.3 Culture dish and coverslip coating 
Culturing neurons and neuroblastoma cells require using substrates, like poly – L – 
lysine which enhances cell adhesion. To prepare the coating substrate, 10 mg poly – 
L – lysine was dissolved in 10 mL ddH2O (1 mg / mL) and filter sterilized by using 
0.2 µm Nalgene filter.  
 Culture dishes were coated with 200 µg / mL; whereas glass coverslips were 
coated with 1 mg/ mL poly – L – lysine solution for 1 hour at room temperature. 
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 Culture dishes were washed 6 times for 5 minutes each with sterile ddH2O. 
 At the final step, ddH2O was taken off and culture dishes were dried.  
2.2.4 PKC activation and inhibition  
PKC activation and inhibition studies were performed by using both mouse 3T3 
fibroblast cells and primary hippocampal neurons. PKC activation studies were 
performed by treatment of mouse 3T3 fibroblast cells with 100 nM PMA for 24 
hours and treatment of hippocampal cultures with 100 nM PMA for 24 hours at 1 
DIV. Inhibition of PKC-α activity was achieved by 30 minutes or 24 hours treatment 
of fibroblasts with 500 nM Gö6976 and by 24 hours Gö6976 treatment of 
hippocampal neurons. Pre-inhibited condition, performed only in hippocampal 
neurons, was achieved by the end of 1 hour 500 nM Gö6976 treatment followed by 
23 hours PMA treatment. Control groups were incubated in 0.1% DMSO containing 
media.  
2.2.5 Amyloid beta 1-42 pre-incubation 
Amyloid beta (1-42) peptide was shown to be neurotoxic in its beta sheet structure 
(Simmons, 1994) and pre-incubation of peptide provides formation of this neurotoxic 
beta sheet structure. Neurotoxicity is usually observed at ~ 6.5 – 22 µM.  
Pre-incubation procedure is indicated below:  
 Lyophilized peptide was dissolve in HPLC grade water to obtain final 
concentration 6 mg / mL.  
 Peptide was diluted to 1 mg / mL with PBS (in which Ca2+ was omitted).  
 Diluted peptide was incubated at 37°C for 24 hours.  
2.2.6 Amyloid beta 1-42 treatment 
Aβ studies were performed by treatment of 1 DIV hippocampal cultures with 7 µM 
pre-incubated Aβ peptide dissolved in hippocampal serum free medium for 24 hours. 
Since peptide was dissolved in water and diluted in PBS in pre-incubation procedure, 
control cells were incubated in hippocampal serum free medium. 
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2.2.7 Quantitative real time PCR and relative quantification of expression  
Specific probe and primers for the genes of interests were purchased from Roche 
Universal Probe Library. Probes and primers used in this study were listed in Table 
2.5. To perform quantitative Real Time Polymerase Chain Reaction (qRT-PCR), 
total RNA was isolated from cultured hippocampal neurons with High Pure RNA 
isolation kit according to the manufacturers’ instructions. RNA concentrations were 
measured by Qubit® Fluorometer using Quant-iT™ RNA, BR Assay Kit. cDNA was 
generated from total RNA using a random hexamer primer and RevertAid™ H minus 
reverse transcriptase (RevertAid™ First Strand cDNA Synthesis Kit) according to 
the manufacturers’ instructions. Gene expression analysis was performed by using 
Roche LightCycler® 480 Real-Time PCR System. All reactions contained cDNA, 
2X LightCycler® 480 Probes Master Mix, 2 µM primer sets and 100 nM probe sets. 
PCR reactions were run using the LightCycler® program, 95°C for 10 minutes 
followed by 45 cycles of 95°C for 10 seconds, 60°C for 30 seconds and 72°C for 1 
second.  
For relative quantification of gene expressions, each primer-probe set was 
standardized (Appendix A) to obtain reaction efficiency values between 1.8 - 2.2 and 
error rate below 0.2 that allows the use of ΔΔCT method in data analysis (Livak, 
2001). This method requires the assignment of one or more housekeeping genes 
(GAPD and actin in this case), which are assumed to be uniformly and constantly 
expressed in all samples. Obtained CT values were normalized against housekeeping 
gene expression levels. This method uses an equation (2.1) to calculate and present 
data as ‘fold change’ (expression level of treated sample / expression level of control 
sample). Each data point is the average of at least two independent samples with two 
replicates. 
  
2.2.8 Immunofluorescence staining of neurons and confocal microscopy 
Primary hippocampal neurons which were grown on poly-L-lysine coated coverslips 
and used for different experimental conditions throughout the study were briefly 
washed with PBS at 37°C. Then, they were simultaneously fixed and extracted with 
2
-ΔΔCT
 = [(CT gene of interest - CT internal control) treated sample –     
(CT gene of interest - CT internal control) control sample)] (2.1) 
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cold 100% methanol at -20°C for 10 minutes. For immunofluorescence staining, 
fixed neurons were blocked in immunofluorescence blocking buffer (10 mg / mL 
BSA, 10% serum) for 1 hour. Neurons were exposed to particular primary antibodies 
[PKC-α (1:500), cyclinD1 (1:1000), cyclinA (1:1000), cyclinB1 (1:1000), cyclinE 
(1:1000), p-tau
ser199
(1:500) and βIII tubulin (1:1000). Primary antibodies were 
diluted in immunofluorescence blocking buffer and neurons were incubated with 
appropriate primary antibodies at 4°C overnight. On the following day, neurons were 
washed with PBS 3 times for 5 minutes each and were blocked in 
immunofluorescence blocking buffer for 1 hour and finally incubated in secondary 
antibodies [Alexa-Fluor®488 (1:1000) or Alexa-Fluor®647 (1:1000)] at 37°C for 1 
hour. Secondary antibodies were also diluted in immunofluorescence blocking 
buffer. Neurons were then washed with PBS 3 times and stained with DAPI for 5 
minutes. Cells were again washed with PBS and mounted with mounting medium. 
Cells were examined with Leica TCS SP2 SE Confocal Microscope with the 63X oil 
objective. All images were obtained by using same gain, brightness-contrast, and 
exposure time settings.  
2.2.9 Congo red staining of neurons and light microscopy 
Congo red staining was performed to visualize Aβ fibrils in primary hippocampal 
cultures. This procedure was applied to live cells, without any fixation. Basic 
protocol followed was: 
 Cells were washed carefully with PBS. 
 1 mL of 0.1% congo red which was already dissolved in H2O was applied on the 
cells for 20 seconds. Cells were then carefully washed with PBS 2 times. 
 Cells were examined with light microscope module of Olympus Fluorescent 
Microscope with the 20X objective. 
2.2.10 Protein extraction, subcellular fractionation and Western blot 
Before starting the procedure for protein extraction, cells were briefly washed with 
PBS and harvested with the help of cell scraper. As it was previously indicated, 
2.5x10
6
 cells / 60 mm culture dish were used for protein extraction and subsequently 
for Western blot. Extraction of the total proteins was performed by using BioVision 
mammalian cell extraction kit according to the manufacturers’ instructions. Nuclear 
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and cytoplasmic fractionation of the lysates was performed with Pierce NE-PER
TM
 
nuclear and cytoplasmic protein extraction kit according to the manufacturers’ 
instructions. Protein concentrations were measured by using Pierce BCA protein 
assay kit and particular BSA standarts.  
For the Western blot analysis, amounts of proteins loaded were 2 μg for nuclear / 
cytoplasmic fractions; 10 μg for total protein samples. Before loading was 
performed, protein samples were mixed with 5X loading buffer and subsequently 
were subjected to denaturation by heating to 99°C for 5 minutes. Then, samples were 
separated on 12.5% denaturing SDS-polyacrylamide gel and separated proteins were 
transferred to nitrocellulose membranes by using a semi-dry blot system. Membranes 
were blocked in the blocking buffer (1% BSA – 5% skim milk in TBS-T) at room 
temperature for 2 hours, then blotted with appropriate primary antibodies [anti PKC-
α (1:500), anti cyclinD1 (1:250), anti pRb (1:100), anti phospho pRb 
Ser807/811(1:100), anti actin (1:100), anti Histone3 (1:1000), anti phospho tau 
Ser199 (1:500), anti p60-katanin (1:100), anti GSK3β (1:500), anti phospho GSK3β 
Ser9 (1:500), anti Bax (1:500), anti Bcl-2 (1:100) and anti-caspase3 (1:500)] diluted 
in blocking buffer at 4°C overnight. Membranes were washed with TBS-T 6 times 
for 5 minutes and then incubated with appropriate HRP conjugated secondary 
antibodies diluted in TBS-T (1:5000) for 1 hour at room temperature. For revealing 
the presence of the protein bands, membranes were treated with ECL Plus or 
SuperSignal® West Femto Western blotting detection reagents and films were 
exposed and developed. Developed films were scanned with densitometer, and the 
densities of the specific bands were quantified and normalized against actin (for 
cytoplasmic fractions and total protein) and Histone3 (for nuclear fractions).  
For reblotting, membranes were washed several times with TBS-T and then stripped 
in stripping buffer for 20 minutes at 80°C. Membranes were washed with TBS-T 3 
times for 5 minutes and blocked in blocking buffer. Same blotting protocol as 
described in detail above was followed for reblotting.  
2.2.11 Proliferation and apoptosis analysis 
To reveal any activated proliferation or apoptosis upon applied treatmens in neurons, 
the PathScan® Apoptosis and Proliferation Multiplex IF kit was used. This kit 
contains primary cocktail composed of 3 primary antibodies which are specific for 
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cleaved PARP Asp214, phospho Histone3 Ser10 and α-tubulin. Cleavage of PARP 
facilitates cellular disassembly and serves as marker for cells undergoing apoptosis. 
Phosphorylation of Histone3 is correlated with chromosome condensation that occurs 
both in mitosis and meiosis. In addition to primary hippocampal neurons, SH-SY5Y 
neuroblastoma cells were also used for this procedure to serve as positive control for 
either proliferation or naturally occuring apoptosis.  
For this purpose, cells were grown on poly-L-lysine coated coverslips and treated 
with appropriate chemicals depending on the experimental condition. Prior to the 
procedure, growth medium was aspirated and cells were briefly washed with 37°C 
PBS. Cells were then fixed with 4% paraformaldehyde (pre-warmed to 37°C) for 15 
minutes at room temperature. Fixative was aspirated and cells were washed with PBS 
3 times for 5 minutes each. For immunofluorescence staining, cells were incubated in 
blocking solution (5% goat serum, 0.3% Triton X-100) for 1 hour at room 
temperature. Then, cells were incubated in primary cocktail, which contains primary 
antibodies for cleaved PARP Asp214, phospho Histone3 Ser10 and α-tubulin, at 4°C 
overnight. Primary coctail was diluted (1:100) in dilution buffer (1% BSA, 0.3% 
Triton X-100). Cells were again washed with PBS 3 times for 5 minutes each and 
incubated in detection cocktail at room temperature for 2 hours in dark. Detection 
coctail was also diluted (1:100) in dilution buffer. Cells were finally washed with 
PBS 3 times for 5 minutes each and mounted with mounting medium. Samples were 
examined with Leica TCS SP2 SE Confocal Microscope with the 63X oil objective. 
All images were obtained using same gain, brightness-contrast, and exposure time 
settings. 
2.2.12 Integrative pixel analysis 
Band densities of Western blot images were analysed by using Photoshop CS4 
Software. Band intensity of each protein blot was calculated by measuring area and 
pixel values. Each calculated value was normalized against actin (for cyctoplasmic 
fraction and total lysate) or Histone3 (for nuclear fraction). 
2.2.13 Neuronal process analysis 
Neurons were analyzed morphologically for their processes. Image-Pro Express 
(Meyer Instruments) software was used to obtain average total process length and 
number values. Sum of total process (axon and dendrites) lengths was obtained for 
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all neurons and then the number was divided by the number of the measured neurons 
and average total process length value per neuron was calculated. Average process 
number values were determined by counting all process numbers and dividing by the 
number of measured neurons. 
2.2.14 Statistical analysis 
Statistical method used in this study was “paired-2 tailed student’s t test”. Test was 
performed with the help of Statistical Package for the Social Sciences (SPSS) 
software. P value under 0.05 was considered statistically significant and indicated 
with “*” in graphs. Relative mRNA expression values were calculated with Relative 
expression software tool (REST, 2009) software, Qiagen. Error bars in the graphs 
were generated using ± SEM values for qRT-PCR and ± SD values for 
immunofluorescence and Western blotting analysis. 
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3.  RESULTS  
3.1 Effects of PKC Activation in Hippocampal Neurons 
3.1.1 PMA and Gö6976 treatments in 3T3 fibroblast cells  
Since it was difficult to observe translocation of PKC upon activation in neurons 
because of specialized and globular morphology of neurons, PKC activation and 
inhibition studies were initially performed with flat cells, mouse 3T3 fibroblast by 
treating the cells with either PMA or Gö6976 for 24 hours (Figure 3.1).  
 
Figure 3.1 : PKC activation and inhibition studies in mouse 3T3 fibroblasts. 
Immunofluorescence labeling was performed for PKC-α (green) and 
nucleus (DAPI, blue). 
According to the immunofluorescence results PKC-α was distributed throughout the 
fibroblast cells in control and Gö6976 treated cells, however, results indicated 
membrane translocation of PKC-α upon 24 hours PMA treatment. This results was 
expected as an indication of PKC activation under normal conditions.  
3.1.2 PKC-α distribution analysis in PKC activated hippocampal neurons  
The aim of this study was to reveal effects of PKC activation on cell cycle re-
activation in neurons under non-degenerative and degenerative conditions in terms of 
cyclins, Cdks and other cell cycle related proteins such as pRb and p60-katanin. For 
this purpose PKC activation was achieved by PMA treatment in physiological 
neurons, as a non-degenerative condition, and in amyloid beta (Aβ) treated neurons, 
as a degenerative condition and changes in cell cycle related proteins were analyzed. 
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Since PKC distribution upon activation was not clear enough in neurons, studies 
were started up with PKC-α distribution analysis (Figure 3.2) As a common known 
knowledge, PKC is normally localized in the cytoplasm of the cell and usually 
translocates to the cell membrane upon activation under normal circumstances. 
However, different PKCs have been shown in the nucleus in various tissues 
(Amadio, 2006). When immunofluorescence analysis was performed, results showed 
that PKC-α was prominently localized in the nuclear regions in PMA treated (PKC 
activation) neurons (Figure 3.2a, middle panel). Whereas in control (Figure 3.2a, left 
panel) and Gö6976+PMA treated (pre-inhibition) neurons (Figure 3.2a, right panel), 
if at all, PKC-α was faintly localized in the nucleus, but mostly throughout the cell 
body and processes of the neurons.  
 
Figure 3.2 : PKC-α analysis of hippocampal neurons after PMA and Gö6976 + 
PMA treatments. Neurons were treated with either PMA for 24 hours or 
pre-inhibited with Gö6976 for 1 hour and then activated for 23 hours 
(Gö6976 + PMA). (a) Immunofluorescence analysis of neurons. Cells 
were labeled with PKC-α (red), DAPI (blue) and neuron specific βIII 
tubulin (green). Scale Bar, 14.5 µm. (b) Western blot of cytoplasmic 
and nuclear protein fractions of control and PMA treated hippocampal 
and quantitative analysis of the blots. (c) Western blot of total cell 
lysate. Bar represents mean values ± SD. 
Consistent with these immunofluorescence results, Western blot analysis of 
cytoplasmic (C) and nuclear (N) fractions also indicated nuclear translocation of 
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PKC-α upon PMA treatment. Band intensities of PKC-α (Figure 3.2b) were 
quantified and normalized against actin for cytoplasmic fraction and Histone3 for 
nuclear fraction. Quantitation results revealed that nuclear/cytoplasmic (N/C) ratio of 
PKC-α was 0.3 for control neurons; whereas the ratio was 0.8 under activation by 
PMA. Nuclear/cytoplasmic ratio was nearly 2.5-fold higher in PMA treated neurons 
compared to control, indicating a translocation of PKC-α into the nucleus. 
Furthermore, Western blot results indicated an increase in expression level of PKC-α 
in PMA treated hippocampal neurons. Bar represents mean values ± SD. 
3.1.3 Effects of PKC activation in mRNA levels of cyclins and cdks 
As previously indicated, when changes in expression level and distribution of PKC-α 
were analyzed, an increase was observed in nuclear localization of PKC-α upon 
PMA treatment. Since PKC-α has also roles in the regulation of cell cycle machinery 
and some cell cycle markers were known to alter in degenerative diseases like AD, 
this study aimed to reveal any possible effets of nuclear PKC-α on the mRNA levels 
of hippocampal neurons in terms of cell cycle markers (Figure 3.3) upon over-
activation.  
 
Figure 3.3 : Changes in relative mRNA levels of cell cycle proteins upon PKC 
activation. Bar represents mean values ± SEM. * p< 0.05. 
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Figure 3.4 : Changes in relative mRNA levels of cell cycle proteins upon Gö6976 
and Gö6976 + PMA treatments. (a) Changes in relative mRNA levels 
of cell cycle proteins upon 24 h Gö6976 treatment and (b) 1 h Gö6976 
treatment followed by 23 h PMA treatment. Bar represents mean values 
± SEM. * p< 0.05. 
In addition to PMA treatment, changes in mRNA levels of hippocampal neurons 
upon PKC inhibition (Figure 3.4a) and 1 hour inhibiton followed by 23 hours 
activation conditions were also analyzed (Figure 3.4b) since we did not know how 
would PKC activation act on the regulation of cell cycle markers. Results indicated a 
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significant increase in cyclinD1 (6.88-fold) and cdk1 (3.04-fold) mRNA levels for 
PMA treated hippocampal neurons (p< 0.05, Figure 3.3). However, under inhibitory 
conditions triggered by Gö6976, there was no significant change in mRNA levels of 
cell cycle proteins (p> 0.05) (Figure 3.4a). In 1 hour pre-inhibiton followed by 23 
hours activation conditions (Figure 3.4b), all analyzed cell cycle markers (except 
cdk4 and p27) were up-regulated compared to control neurons. When cyclinD1 
mRNA was analyzed, a ~ 4-fold increase was observed. However, in PMA treated 
condition, the increase was ~ 8-fold. One hour pre-inhibition of PKC with Gö6976 
down-regulated effect of PKC on cyclinD1 expression. 
3.1.4 Analysis of protein levels and distibutions of cyclins in PMA treated 
neurons  
When mRNA analysis was performed results indicated elevated mRNA levels in 
couple of cell cycle markers only under PMA treatment. For instance, there was no 
significant change in mRNA levels of only Gö6976 treated hippocampal neurons 
(Figure 3.4a). Altough changes in mRNA levels are important for the cells, changes 
in protein levels and distributions are also important since translation of mRNA into 
protein determines the functionality of the protein. For this reason, changes in protein 
levels were also analyzed for cyclinA, cyclinB, cyclinD1 and cyclinE with 
immunofluorescence analysis. 
When immunofluorescence analysis was performed for cyclinA (Figure 3.5a) it was 
seen that besides being expressed under all of the three experimental conditions, 
cyclinA was also present in control neurons. When integrative pixel analysis was 
performed for the immunofluorescence image of cyclinA (Figure 3.5b), it could be 
seen that cyclinA levels were similar in PMA and Gö6976 + PMA treated neurons. 
However, in Gö6976 treated cells where PKC inhibition was performed for 24 hours, 
there was a decrease in cyclinA levels compared to control neurons.  
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Figure 3.5 : Immunofluorescence analysis of cyclinA protein levels after PMA and 
Gö6976 treatments. (a) Neurons were treated for 24 hours with either 
0.1% DMSO (control) or PMA or Gö6976 (PKC inhibition) or 
differently neurons were pre-inhibited with Gö6976 for 1 hour and then 
PMA treated for 23 hours (Gö6976+PMA). Cells were labeled with 
cyclinA (cycA, red) and neuron specific βIII tubulin (green). (b) 
Arbitrary fluorescence units (AFU) analysis of immunofluorescence 
image of cyclinA. Bar represents mean values ± SD. * p< 0.05. 
When immunofluorescence analysis was performed for cyclinB1 (Figure 3.6a), low 
level of protein was faintly seen in all experimental conditions including control 
group. Integrative pixel analysis for immunofluorescence image of cyclinB1 (Figure 
3.6b) revealed that cyclinB1 levels did not change much depending on the different 
treatments. All four conditions contained similar amounts of expressed cyclinB1 
protein. 
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Figure 3.6 : Immunofluorescence analysis of cyclinB1 protein levels after PMA and 
Gö6976 treatments. (a) Neurons were treated for 24 hours with either 
0.1% DMSO (control) or PMA or Gö6976 (PKC inhibition) or 
differently neurons were pre-inhibited with Gö6976 for 1 hour and then 
PMA treated for 23 hours (Gö6976+PMA). Cells were labeled with 
cyclinB1 (cycB, red) and neuron specific βIII tubulin (green). (b) 
Integrative pixel analysis as arbitrary fluorescence units (AFU) for 
immunofluorescence image of cyclinB1.  
CyclinD1 immunofluorescence analysis (Figure 3.7a) revealed completely different 
results compared to cyclinA and cyclinB. Integrative pixel analysis for 
immunofluorescence image of cyclinD1 (Figure 3.7b) indicated similar results as 
changes in mRNA levels, cyclinD1 levels were elevated in PMA treated neurons. 
cyclinD1 was found to be localized in the cell body, or even in the nuclear regions of 
neurons. 
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Figure 3.7 : Immunofluorescence analysis of cyclinD1 protein levels after PMA and 
Gö6976 treatments. (a) Neurons were treated for 24 hours with either 
0.1% DMSO (control) or PMA or Gö6976 (PKC inhibition) or 
differently neurons were pre-inhibited with Gö6976 for 1 hour and then 
PMA treated for 23 hours (Gö6976+PMA). Cells were labeled with 
cyclinD1 (cycD, red) and neuron specific βIII tubulin (green). Arrows 
indicate nuclear cyclinD1. (b) Integrative pixel analysis as arbitrary 
fluorescence units (AFU) for immunofluorescence image of cyclinD1. 
Bar represents mean values ± SD. * p< 0.05. 
Finally, when cyclinE protein levels were checked (Figure 3.8a), cyclinE was found 
to be expressed in all four experimental conditions. Integrative pixel analysis showed 
that (Figure 3.8b), cyclinE levels were increased in PMA and Gö6976 + PMA treated 
neurons; however, in Gö6976 treated cells cyclinE level was similar to control 
neurons. 
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Figure 3.8 : Immunofluorescence analysis of cyclinE protein levels after PMA and 
Gö6976 treatments. (a) Neurons were treated for 24 hours with either 
0.1% DMSO (control) or PMA or Gö6976 (PKC inhibition) or 
differently neurons were pre-inhibited with Gö6976 for 1 hour and then 
PMA treated for 23 hours (Gö6976+PMA). Cells were labeled with 
cyclinE (cycE, red) and neuron specific βIII tubulin (green). (b) 
Integrative pixel analysis as arbitrary fluorescence units (AFU) for 
immunofluorescence image of cyclinE. Bar represents mean values ± 
SD. * p< 0.05. 
3.1.5 CyclinD1 analysis in hippocampal neurons upon PMA mediated PKC 
activation  
Since increase was specifically observed in both mRNA and protein levels of 
cyclinD1 upon PKC activation, cyclinD1 was chosen for further detailed analysis. 
PKC-α was shown to be a negative regulator of cyclinD1 in intestinal epithelial cells 
(Frey, 2000), and a positive regulator of cyclinD1 in gliomal cells (Besson and Yong, 
2000). Results in this study showed that PKC-α was condensed in the nuclei of 
neurons upon activation (Figure 3.2, middle panel). To reveal whether this nuclear 
PKC-α had any possible effects on cyclinD1, detailed analysis for cyclinD1 was 
performed in PKC activated and inhibited neurons (Figure 3.9).  
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Figure 3.9 : CyclinD1 analysis in hippocampal neurons upon PMA treatment. (a) 
mRNA levels of cyclinD1 (cycD) in PKC activated (PMA) and 
inhibited (Gö6976) hippocampal neurons were quantified by qRT-PCR. 
Calculations were performed according to ΔΔCT method, where 
expression of control is accepted 1 (red line). Bar represents mean 
values ± SEM. * p< 0.05. (b) Western blot of total protein lysate of 
control and PKC activated (PMA) hippocampal neurons (b, left). 
Lysates were separated with SDS-PAGE and probed with cycD and 
actin antibody. Quantitative analysis of the blots (b, right). Band 
intensities were normalized against actin. Bar represents mean values ± 
SD. * p< 0.05. (c) Treated hippocampal neurons immunolabeled for 
cycD (red in the lover panel; grey in the upper panel) and neuron 
specific βIII tubulin (green). Scale Bar, 14.5 µm. (d) Western blot of 
cytoplasmic and nuclear protein fractions of control and PKC activated 
(PMA) hippocampal neurons (left). Membrane was probed with cycD 
antibody and Histone3 or actin antibodies as an internal control. 
Quantitative analysis of the blots (right). Band intensities of cycD were 
normalized against actin for cytoplasmic fraction, and Histone3 for 
nuclear fraction. Bar represents mean values ± SD. 
Results indicated a significant, 6.88-fold increase in cyclinD1 mRNA levels of PMA 
treated hippocampal neurons (p< 0.05); whereas under inhibitory conditions 
triggered by Gö6976, mRNA levels of cyclinD1 were 0.96 (p> 0.05), similar to 
control groups (Figure 3.9a). Given that a significant change in mRNA levels of 
cyclinD1 was observed only in PMA treated hippocampal neurons, hence, further 
studies were performed to determine whether this increase was corresponding to an 
increase in the protein level, too. To reveal that, Western blot analysis was performed 
for total protein lysate in PKC activated hippocampal neurons. Blot results also 
indicated nearly a 3-fold increase in cyclinD1 protein level (Figure 3.9b). 
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Since protein localization is as crucial as its expression level for its function, 
immunofluorescence analysis was also performed in order to observe localization of 
cyclinD1 within the neurons (Figure 3.9c). PKC activated hippocampal neurons were 
labeled for cyclinD1 (cycD) and neuron specific βIII tubulin simultaneously. 
Immunofluorescence results pointed out a remarkable nuclear accumulation of 
cyclinD1 in PKC-α activated condition (Figure 3.9c). In order to further analyze and 
quantify the shuttling of cyclinD1, nuclear/cytoplasmic fractioning of PKC activated 
hippocampal neurons was performed and fractions were analyzed with Western 
blotting (Figure 3.9d, left). Results indicated that nuclear/cytoplasmic ratio of 
cyclinD1 was 0.6 for control neurons, while under activation condition by PMA, the 
ratio was 3.3 (Figure 3.9d, right). Nuclear/cytoplasmic ratio was increased 5-fold 
compared to control group upon PKC activation, which also confirmed nuclear 
translocation of cyclinD1. 
3.1.6 Analysis of pRb and ppRb protein levels upon PKC activation and 
inhibition  
Since pRb is one of the best characterized substrate of cyclinD1, changes in pRb and 
ppRb levels were investigated. In addition, loss of pRb was found to interfere with 
differentiation and can re-activate cell cycle machinery even in terminally 
differentiated cells (Endo and Goto 1992). Increase in both mRNA and protein levels 
of cyclinD1 was observed in PKC activated cells. Therefore changes on pRb and 
ppRb protein levels were also investigated by immunofluorescence (Figure 3.10a) 
and Western bloting (Figure 3.10c). Quantitation results indicated nearly 50% 
decrease in pRb protein level upon PKC activation (Figure 10.b, d – left), and this 
decrease was accompanied by nearly 50% increase in ppRb protein level (Figure 
3.10d – right). 
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Figure 3.10 : Analysis of pRb and ppRb protein levels in hippocampal neurons after 
PMA and Gö6976 treatments. (a) Treated hippocampal neurons 
immunolabeled for pRb (red in the lover panel; grey in the upper panel) 
and neuron specific βIII tubulin (green). (b) Integrative pixel analysis of 
the blots. (c) Total protein lysate of control and PKC activated (PMA) 
hippocampal neurons were separated with SDS-PAGE and probed with 
pRb, ppRb and actin antibody. (d) Quantitative analysis of the blots was 
performed by normalizing band intensities against actin. Bar represents 
mean values ± SD. * p< 0.05.  
3.1.7  Morphological analysis of hippocampal neurons 
Visual observations indicated that PMA treated neurons had shorter process 
formations which led me to analyze the morphology and quantify the differences 
between the groups (Figure 3.11a). To this aim, process lengths of neurons were 
measured by using Image-Pro Express (Meyer Instruments) software. To assess 
whether pre-inhibition of PKC with Gö6976 would reverse the effects of activated 
PKC in terms of neuronal process features, sequential inhibition-activation condition 
of PKC was performed. Measurement results showed that average total process 
lengths of PMA treated neurons decreased nearly 25% (p< 0.05) compared to control 
neurons, whereas average total process lengths of neurons in which PKC was pre-
inhibited with Gö6976 were similar to control neurons (p> 0.05) (Figure 3.11b). Yet, 
average process numbers of PMA treated neurons increased nearly 50% (p< 0.05) 
compared to control neurons, while in Gö6976 pre-treated neurons process numbers 
were even less than control neurons (p< 0.001) (Figure 3.11c). Therefore, under PKC 
activation, neuronal processes were shortened, while process numbers were increased 
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significantly. Moreover, microtubule density was condensed in the cell body of PMA 
treated neurons.  
 
Figure 3.11 : Morphological analysis of hippocampal neurons. Morphological 
analysis of hippocampal neurons after PMA and Gö6976 treatments. 
Analysis was performed by using Image-Pro Express (Meyer 
Instruments) software. (a) Hippocampal neurons were immunolabeled 
for neuron specific βIII tubulin. (b) Average total process lengths 
analysis of hippocampal neurons in control, PMA treated and 1 hour 
Gö6976 + 23 hours PMA treated conditions. (c) Average process 
number analysis of hippocampal neurons in control, PMA treated and 1 
hour Gö6976 + 23 hours PMA treated conditions. Scale Bar, 47.02µm. 
Bar represents mean values ± SD. * p< 0.05. 
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3.1.8 Determination of p-tau and p60-katanin levels upon PKC activation 
Microtubule re-organization differences were observed in PKC activation conditions. 
Hence, p-tau and p60-katanin protein levels were also analyzed since they are 
important players of neuronal microtubule organization (Baas and Qiang, 2005; 
Johnson and Stoothoff, 2004). Therefore, changes in protein level of p-tau (Figure 
3.12a) was also analyzed in PMA treated neurons and results were compared with 
control neurons. Western blot results indicated 2.6-fold increase (p< 0.05) in p-tau 
protein levels upon PMA treatment (Figure 3.14b). Since p-tau dissociates from 
microtubules, increase in p-tau levels would result in more accessible microtubules, 
which would serve as substrates for microtubule severing protein p60-katanin (Baas 
and Qiang, 2005). Hence, changes in p60-katanin levels in PMA treated neurons 
(Figure 3.12a) were quantified and 1.5-fold increase was observed (p< 0.05) in PMA 
treated neurons compared to control neurons (Figure 3.14b). 
 
Figure 3.12 : P-tau and p60-katanin protein levels in PMA treated hippocampal 
neurons. (a) Western bloting analysis of p-tau and p60-katanin protein 
lysates in control and PMA treated neurons. Control and PKC activated 
hippocampal neurons were immunolabeled for p-tau (Ser
199
) and p60-
katanin proteins. (b) Quantitative analysis of the blots were achieved by 
normalizing band intensities of p-tau and p60-katanin against actin. Bar 
represents mean values ± SD. * p< 0.05. 
3.1.9 Phosphorylation analysis of GSK3β upon PMA treatment 
For proliferating cells, cyclinD1, marker for G0 exit, needs to be up-regulated so that 
cells could proceed through G1 phase. CyclinD1 accumulates in the nucleus 
throughout G1 phase, and re-localizes to the cytoplasm as cells proceed to S phase. 
Orchestration of cyclinD1 translocation is carried out by GSK3β. Activated GSK3β 
is one of the main players for the transport of cyclinD1 back to the cytoplasm that 
takes place when cells exit G1 to proceed through S phase (Baldin, 1993; Diehl, 
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1998). GSK3β is also one of the substrates of PKC and has a role in tau 
phosphorylation. Findings in this study demonstrated that PKC activation increased 
nuclear accumulation of cyclinD1, phosphorylation of Rb and tau. Hence, 
phosphorylation analysis for GSK3β was performed in total protein lysates of PMA 
treated hippocampal neurons (Figure 3.13).  
 
Figure 3.13 : GSK3β and p-GSK3β analysis in PMA treated hippocampal neurons. 
(a) Western blot analysis of GSK3β and p-GSK3β protein lysates in 
control and PMA treated neurons. Control and PKC activated 
hippocampal neurons were immunolabeled for GSK3β and p-GSK3β 
(Ser9). (b) Quantitative analysis of the blots were achieved by 
normalizing band intensities of GSK3β and p-GSK3β against actin. Bar 
represents mean values ± SD. 
When phorsphorylation of GSK3β was analyzed by Western blotting, there was no 
significant change (p> 0.05) observed between control and PMA treated neurons. 
3.1.10 Proliferation and apoptosis analysis in PMA treated neurons 
Increase in nuclear cyclinD1 is associated with proliferation in mitotic cells; while in 
neurons increase in nuclear cyclinD1 (Nagy, 2007; Herrup and Yang, 2007; Atabay 
and Karabay, 2011) and p-tau (Lee, 2001; Atabay and Karabay, 2011) evoke 
neurodegeneration. To reveal any possible activation of proliferation or apoptosis 
upon PKC activation, ThePathScan® Apoptosis and Proliferation Multiplex IF kit 
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was used. The kit contains primary cocktail composed of three primary antibodies 
specific for α-tubulin, phospho Histone3 Ser10 and cleaved PARP Asp214 (Figure 
3.14a). Cleavage of PARP facilitates cellular disassembly and serves as a marker for 
cells undergoing apoptosis, while phosphorylation of Histone3 is correlated with 
chromosome condensation that occurs both in mitosis and meiosis. Results indicated 
that PMA treatment triggered neither proliferation nor apoptosis in neurons (Figure 
3.14a, middle). Whereas, in physiological mitotic cells, both proliferation and 
naturally occurring apoptosis were observed (Figure 3.14a, right). 
 
Figure 3.14 : Apoptosis and proliferation analysis of hippocampal neurons after 
PMA treatment. (a) Apoptosis and proliferation analysis of 
hippocampal neurons and mitotic cells. Cells were immunolabeled for 
cleaved PARP (blue, indication of apoptosis), phospho Histone3 (green, 
indication of proliferation) and α-tubulin (red). (b, c) Western blot 
image of total protein lysate of control and PKC activated (PMA) 
hippocampal neurons. Lysates were separated with SDS-PAGE and 
probed with Bax, Bcl-2 (b), caspase3 (c) and actin (b, c) antibodies.  
PMA treated cells were also analyzed for Bax pro-apoptotic protein, Bcl-2 anti-
apoptotic protein (Figure 3.14b) and caspase3 protease (Figure 3.14c). There was no 
significant difference in Bax protein levels between control and PMA treated neurons 
(Figure 3.14b, upper) (p> 0.05). When Bcl-2 levels were analyzed (Figure 3.14b, 
middle), there was no protein band observed in control neurons, while it was obvious 
in PMA treated neurons. Immunoblotting for caspase3 protein was performed for 
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both control and PMA treated neurons (Figure 3.14c). Findings indicated that pro-
caspase3 levels were increased in PMA treated cells, but there was no indication for 
increase in cleaved caspase3. 
3.2 Effects of PKC Activation in Amyloid Beta Treated Hippocampal Neurons 
3.2.1 Observation of amyloid beta plaques in hippocampal neurons 
The aim of this study was to reveal effects of PKC activation on cell cycle re-
activation in neurons under non-degenerative and degenerative condition. In this part 
of the study, hippocampal neurons were treated with Aβ in order to trigger amyloid 
based degeneration. It is known that concentrations between 6.5 – 22 µM of Aβ 
causes neurodegeneration, hence, 7 µM final concentration of Aβ was chosen in this 
study since the aim was to only initiate degeneration rather than obtain totally 
degenerated neurons. Aβ plaques that were observed were monitored with congo red 
staining by light microscopy (Figure 3.15). 
 
Figure 3.15 : Congo red staining of hippocampal neurons for Aβ plaques. Congo red 
staining was performed for hippocampal neurons following 24 hours 7 
µM Aβ treatment. Image was obtained by using light microscopy. 
Arrowheads show plaque depositions. 
 
 
 
 
 
    
50 
 
3.2.2 Expression level and subcellular distribution analysis of PKC-α upon PKC 
activation in amyloid beta treated neurons 
PKC is one of the proteins that have altered expression levels in AD and its activity 
and translocation has been consistently found to be reduced in AD patients’ 
fibroblasts and brains (Battaini, 1999; Gasparini, 1998). In the previous section of the 
study, the aim was to investigate the effects of PKC activation in hippocampal 
neurons under their physiological conditions. In this part of the study, the aim was to 
reveal the effects of PKC under neurodegenerative condition such as AD. For this 
purpose, PKC activation studies were performed in Aβ treated neurons in order to 
compare discrepancies in PKC signaling pathway between physiological and Aβ 
treated neurons in terms of changes in protein levels and distributions of cyclins, 
specifically cyclinD1 and PKC-α itself.  
 
Figure 3.16 : Immunofluorescence and Western blot analysis of PKC-α protein 
levels after Aβ and PMA treatments. Neurons were treated for 24 hours 
with either 0.1% DMSO (control) or Aβ (amyloid) or neurons were pre-
treated with Aβ for 24 hours and then PMA treated for an additional 24 
hours (amyloid + PMA). (a) Cells were labeled with PKC-α (red), 
neuron specific βIII tubulin (green) antibodies and DAPI (blue). (b) 
Western blot analysis of PKC-α (b,left) and quantitation of the blots (b, 
right). Bar represents mean values ± SD.  
For this purpose, protein expression and subcellular distribution of PKC-α were 
analyzed in Aβ treated hippocampal neurons (Figure 3.16). According to 
immunofluorescence analysis (Figure 3.16a), PKC-α was distributed throughout the 
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cell (cell body and processes) in control neurons (Figure 3.16a, left panel). When 
neurons were treated with 7 µM Aβ for 24 hours (Figure 3.16a, middle panel), 
distribution of PKC-α was not changed prominently. When neurons were 
sequencially treated with Aβ and PMA for 24 hours each, PKC-α level was faintly 
decreased (Figure 3.16a, right panel). When Western blot analysis was performed for 
the same experimental conditions (Figure 3.16b, left), quantitation results showed 
that there was no significant change in PKC-α protein levels between control and 
experimental neurons (Figure 3.16b, right). 
3.2.3 Effects of PKC activation on mRNA levels of cyclins in amyloid beta 
treated hippocampal neurons  
As indicated in the previous part, PMA mediated PKC activation significantly 
increased mRNA level of cyclinD1 and cdk1 (Figure 3.3). qRT-PCR analysis was 
again performed to reveal effects of PKC activation under Aβ treated condition in 
hippocampal neurons (Figure 3.17). When qRT-PCR results were analyzed, it was 
seen that there was no significant change in mRNA levels of cell cycle proteins in Aβ 
treated hippocampal neurons (Figure 3.17a). Furthermore, mRNA levels of cell cycle 
proteins in 24 h Aβ and 24 hours PMA treated hippocampal neurons were similar to 
control neurons (Figure 3.17b). Differently from only PMA treated neurons (Figure 
3.3), Aβ treated neurons did not response to PMA mediated PKC activation, in terms 
of increase in cyclinD1 mRNA level.  
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Figure 3.17 : Changes in relative mRNA levels of cell cycle proteins upon Aβ and 
PMA treatments. (a) Changes in relative mRNA levels of cell cycle 
proteins upon 24 h Aβ treatment and (b) 24 h Aβ treatment followed by 
24 hours PMA treatment. Boxes represents the interquartile range of 
observations. The dotted line shows the median gene expression. Line 
represents  relative gene expression level for control cells which is 
accepted 1. Bar represents mean values ± SEM. * p< 0.05. 
3.2.4 Analysis of protein levels and distibutions of cyclinD1 in amyloid beta 
treated hippocampal neurons  
mRNA analysis did not indicate any significant change in mRNA levels neither in 
Aβ treated nor in Aβ + PMA treated neurons (Figure 3.17). Though, 
immunofluorescence analysis was performed to see whether protein level or 
distribution of cyclinD1, which has been found to be up-regulated in PMA treatment, 
was changed upon amyloid treatment.  
When immunofluorescence analysis was performed for cyclinD1 (Figure 3.18), 
integrative pixel analysis results indicated increase only in PMA condition. CyclinD1 
levels in Aβ and Aβ + PMA condition were similar to control neurons (Figure 
3.18b). Nuclear localization of cyclinD1 was not observed in control, Aβ and Aβ + 
PMA treated neurons but clearly observed in only PMA treated ones (Figure 3.18a).  
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Figure 3.18 : Immunofluorescence analysis of cyclinD1 protein levels after Aβ and 
PMA treatments. (a) Neurons were treated for 24 hours with either 
0.1% DMSO (control) or PMA or Aβ or neurons were pre-treated with 
Aβ for 24 hours and then PMA treated for an additional 24 hours (Aβ + 
PMA). Cells were labeled with cyclinD1 (cycD, red) and neuron 
specific βIII tubulin (green) antibodies. (b) Integrative pixel analysis as 
arbitrary fluorescence units (AFU) for immunofluorescence image of 
cyclinD1. Bar represents mean values ± SD. * p< 0.05. 
3.2.5 Analysis expression level and subcellular distribution of pRb upon PKC 
activation in amyloid beta treated neurons 
As indicated in the first part of the study, pRb is one of the best characterized 
substrate of cyclinD1 and loss of pRb was found to interfere with differentiation 
(Endo and Goto, 1992). In the first part of the study, quantitation results indicated a 
nearly 50% decrease in pRb protein level upon only PKC activation (Figure 3.10). 
Here, in the second part of the study, immunofluorescence analysis was performed 
for pRb in amyoid or amyloid+PMA treated neurons (Figure 3.19a) in addition to 
control and only PMA treated cells. Integrative pixel analysis results indicated more 
than 50% decrease in pRb protein level upon only PKC activation (PMA). pRb levels 
were similar between conrol and Aβ or Aβ + PMA treated neurons (Figure 3.19b). 
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Figure 3.19 : Immunofluorescence analysis of pRb protein levels after Aβ and PMA 
treatments. (a) Neurons were treated for 24 hours with either 0.1% 
DMSO (control) or PMA or Aβ or neurons were pre-treated with Aβ for 
24 hours and then PMA treated for an additional 24 hours (Aβ + PMA). 
Cells were labeled with pRb (red) and neuron specific βIII tubulin 
(green) antibodies. (b) Integrative pixel analysis as arbitrary 
fluorescence units (AFU) for immunofluorescence image of pRb. Bar 
represents mean values ± SD. * p< 0.05. 
3.2.6 Morphological analysis of amyloid beta treated hippocampal neurons  
Morphological analysis of the neurons has revealed that under PKC activation, 
neuronal processes were shortened, while process numbers were increased 
significantly (Figure 3.11). Similar morphological analysis was performed for 
amyloid beta treated neurons to reveal effects of amyloid on neuronal processes. 
Results indicated that average total process lengths of amyloid and amyloid+PMA 
treated neurons were similar to control neurons (p> 0.05) (Figure 3.20b), however, 
there was a nearly 50% decrease  in average process number of amyloid and 
amyloid+PMA treated neurons (p< 0.001) (Figure 3.20c).  
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Figure 3.20 : Morphological analysis of amyloid beta treated hippocampal neurons. 
(a) Hippocampal neurons were immunolabeled for neuron specific βIII 
tubulin. (b) Average total process lengths analysis of hippocampal 
neurons in control, PMA, Aβ, Aβ + PMA treated conditions. (c) 
Average process number analysis of hippocampal neurons in control, 
PMA, Aβ, Aβ + PMA treated conditions. Scale Bar, 47.02µm. Bar 
represents mean values ± SD. * p< 0.05. 
3.2.7 Analysis expression level and subcellular distribution of p-tau,  p60-
katanin and GSK3β upon PKC activation in amyloid beta treated neurons 
Microtubule re-organization differences were observed in PKC activation conditions 
and hence, p-tau and p60-katanin protein levels were analyzed (Figure 3.12). In this 
part of the study, changes in protein level of p-tau (Figure 3.21a) and p60-katanin 
(Figure 3.21b) were also analyzed. Western blot quantitation did not reveal 
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significant differences between control and treated neurons for p-tau (Figure 3.21a) 
and p60-katanin levels were similar between all three conditions (p> 0.05) (Figure 
3.21b).  
 
Figure 3.21 : Western blot analysis of p-tau and p60-katanin protein levels after Aβ 
and PMA treatments. Neurons were treated for 24 hours with either 
0.1% DMSO (control) or Aβ or neurons were pre-treated with Aβ for 
24 hours and then PMA treated for an additional 24 hours (Aβ + PMA). 
(a, b) Western blot analysis and quantitation of the blots for p-tau (a) 
and p60-katanin (b). Bar represents mean values ± SD.  
3.2.8 PKC activation triggered neither proliferation nor apoptosis in amyloid 
beta treated neurons 
To reveal any possible activation of proliferation or apoptosis upon Aβ treatment 
ThePathScan® Apoptosis and Proliferation Multiplex IF kit was used. There was no 
indication for either proliferation or apoptosis under these experimental conditions 
(Figure 3.22a). Aβ treated cells were also analyzed for Bax pro-apoptotic protein and 
Bcl-2 anti-apoptotic protein by Western blot (Figure 3.22b). Quantitation of Western 
blot indicated a significant increase in Bax/Bcl-2 ratio between control and Aβ 
treated and between control and Aβ + PMA treated neurons (p< 0.05) (Figure 3.22c). 
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Figure 3.22 : Apoptosis and proliferation analysis of hippocampal neurons after Aβ 
treatment. (a) Apoptosis and proliferation analysis of neurons and 
mitotic cells. Cells were immunolabeled for cleaved PARP (blue), 
phosphor Histone3 (green) and α-tubulin (red). (b) Western blot image 
of total protein lysate of control, amyloid treated and sequencially 
amyloid teated and PKC activated (amyloid+PMA) hippocampal 
neurons. Lysates were probed with Bax, Bcl-2 and actin antibodies. (c) 
Quantitation of Western blot image in terms of Bax/Bcl2 ratio. Bar 
represents mean values ± SD. * p< 0.05.  
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4.  DISCUSSION AND CONCLUSIONS 
Since neurons are terminally differentiated cells that are restricted from reverting 
back to the cell cycle, stringent set of control mechanisms are required to keep them 
at G0 phase. Revealing the effects of PKC activation on cyclins, especially cyclinD1 
is crucial in terms of understanding whether it would lead neurons to cell cycle re-
activation as indicated by PKC’s involvement with neurodegeneration. For instance, 
PKC activity has been consistently found to be reduced in AD patients’ fibroblasts; 
decreased activity and expression of particular PKC isoforms have also been 
demonstrated in postmortem brain cortex of AD subjects. Here, it was shown that 
PKC activation changed distribution of both PKC-α and cyclinD1 in neurons under 
their physiological condition. PKC activation also increased phosphorylation of pRb, 
triggered microtubule re-organization and increased protein levels of p-tau and p60-
katanin. Yet, it did not activate any apoptotic or proliferative signaling pathway via 
up-regulation of cyclinD1 which has been shown to be involved in degeneration of 
neurons. Experimental results indicated that cyclinD1 might also be related with 
neuronal differentiation as suggested by a number of increasing contemporary 
studies. 
Since it was not clear enough in neurons, the effects of PKC activation on 
distributional and expressional orchestration of PKC-α was investigated in 
physiological conditions. Although PKC-α usually functions in cytoplasm and 
membrane fractions of the cells, there has been evidence indicating a role for PKC-α 
in nuclear compartments such as in replication and transcription (Martelli, 2006). 
Consequently, it was found that PKC-α was prominently translocated to the nuclei of 
hippocampal neurons upon activation, indicating a possible nuclear role for neuronal 
PKC-α. However, when neurons were treated with Aβ for 24 hours, as a degenerative 
condition, they did not response to PMA treatment in terms nuclear  localization of 
PKC-α. It is possible that direct Aβ – PKC interaction was observed through PKC 
pseudosubstrate domain of Aβ (Lee, 2004) and prevented activation by PMA.  
As cytoplasmic PKC-α could serve either activating or inhibitory functions, it is also 
likely that nuclear PKC-α could either up- or down-regulate transcription of the 
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target genes, such as cyclinD1, in this case. For instance, in hippocampal neurons, it 
was found that cyclinD1 was up-regulated both in mRNA and protein levels upon 
PMA mediated PKC activation. Yet, pre-inhibition of PKC with Gö6976 before 
activation caused a reduction in the expression level of cyclinD1 supporting the 
specificity of the effect of PKC activation on cyclinD1 expression. However, exact 
mechanism of cyclinD1 up-regulation by PKC in neurons is still elusive and detailed 
mechanism for transcriptional control needs to be elucidated in further studies. Yet, 
changes in mRNA level did not correspond exactly to the changes in protein level. 
For instance mRNA increase in cyclinD1 upon PMA treatment was observed to be 
~8-fold, however, changes in protein level of cyclinD1 was nearly 3-fold. Yet, it is 
known that mRNA levels cannot be always used to predict protein levels. There are 
many factors such as RNA secondary structure, 3' UTR (Un-Translated Region), post 
translational modification, protein-protein interactions, other protein stabilizing 
molecules, etc… effecting rate of mRNA and protein turnover. There may also be 
miRNAs (micro RNAs) that have roles in affecting cyclinD1 mRNA stability, as 
well. 
Differently from only PMA treated neurons, in Aβ treated and Aβ + PMA treated 
neurons neither mRNA nor protein level and distribution of cyclinD1 was changed. It 
can be speculated that although Aβ treatment did not initiate a full 
neurodegeneration, it probably caused impairments in PKC signaling pathway as a 
results of direct Aβ – PKC interaction and prevented nuclear accumulation of PKC-α 
upon activation and its subsequent influences on cyclinD1.  
It is widely accepted that, for proliferating cells, cyclinD1, a marker for G0 exit, 
needs to be up-regulated so that cells could proceed through G1 phase. According to 
the known model, cyclinD1 accumulates in the nucleus throughout G1 phase, and re-
localizes to the cytoplasm as cells proceed to S phase (Baldin, 1993; Diehl 1998). 
According to conventional knowledge, cell cycle proteins are thought to be silenced 
in terminally differentiated neurons. However, there are many recent studies 
indicating expression of cyclinD1, cyclinA and other cell cycle related proteins in 
neurons and attributing cell cycle independent roles for them such as participating in 
synaptic plasticity and differentiation (Schmetsdorf, 2007; Richter, 2001; Bowser 
and Smith, 2002; Ross and Risken, 1994; Ross, 1996). Based on findings in this 
study which demonstrated that PKC activation increased nuclear accumulation of 
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cyclinD1, it could be tempting to predict that neurons attempted to leave G0 phase to 
proceed through G1 phase. However, there was no up-regulation of cell cycle 
progression indicator downstream cyclin, cyclinA, in either transcriptional or 
translational level. These findings may also contribute to the information of cell 
cycle independent role for nuclear cyclinD1 in neurons. 
pRb is one of the substrates of cyclinD1. Hyper-phosphorylated pRb (ppRb) is 
inactive form of pRb and present in late G1, S, G2, and M phases of cycling cells 
(Nagy, 2007). Furthermore, loss of pRb was found to interfere with differentiation 
and can re-activate cell cycle machinery even in terminally differentiated cells 
(Herrup and Yang, 2007). Results showed a decrease in pRb level and it is 
compensated by an increase in ppRb level. In dividing cells, increase in ppRb levels 
is accompanied by an increase in S phase cyclin, cyclinA. However, in this study, 
neither mRNA (Figure 3.3) nor protein levels or subcellular distributions of cyclinA 
(Figure 3.5) were changed upon PKC activation. Thus, unlike mitotic cells, increase 
in ppRb level in neurons did not result in further progress in cell cycle. Yet, decrease 
in pRb level appeared together with retraction of neuronal processes (Figure 3.11a, 
middle), and this is consistent with the role of pRb in differentiation (Ezhevsky, 
1997). Decreased pRb level caused shorter process formation towards more globular 
structure in neurons.  
Observations indicated changes in morphology of neurons in terms of microtubule 
lengths and process numbers. Hence, neurons were analyzed to obtain average total 
process lengths and average process numbers (Figure 3.11b and 3.11c, respectively). 
Results indicated that average total process lengths were decreased in PKC activated 
neurons (Figure 3.11a, middle and Figure 3.11b). However, in neurons that PKC was 
pre-inhibited with Gö6976 before activation (Figure 3.11a, right and Figure 3.11b), 
average total process lengths were similar to control neurons (Figure 3.11a, left and 
Figure 3.11b). In addition to this, average process number was increased nearly 50% 
in PKC activated neurons, and there was a slight decrease in the number of processes 
per neuron in pre-inhibition condition (Figure 3.11c). Morphological changes in 
neuronal branches occur as a result of microtubule re-organization, and in this study, 
PKC activated neurons also exhibited re-organization in neuronal processes. 
Furthermore, when neurons were treated with Aβ and Aβ + PMA, average total 
process lengths were similar to control neurons (Figure 3.20b) while in PMA treated 
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neurons process lengths were decreased (Figure 3.11b, 3.20b) as an indication of 
microtubule re-organization. It can be concluded that Aβ prevented microtubule re-
organization upon PMA treatment probably as a result of Aβ – PKC interaction, as 
previously indicated. Despite the fact that average total process lengths did not 
changed upon Aβ treatments, average process numbers were decreased in both Aβ 
and Aβ + PMA treated neurons implying amyloid caused impairments in minor 
process formations which may lead to neurodegeneration in further timepoints.   
The main players taking part in microtubule re-organization in terms of neuronal 
differentiation are p-tau and p60-katanin (Vale, 2000; Baas and Qiang, 2005). In this 
content, Western blot results indicated 2.6-fold increase in p-tau protein levels upon 
PMA treatment (Figure 3.12a). tauSer199 has been shown to be phosphorylated (p-
tauSer199) by GSK3β of which PKC is an upstream effector. As there was no 
increase observed in the phosphorylation level of GSK3β upon activation of PKC 
(Figure 3.13) under this experimental conditions, it could be likely that tau 
phosphorylation was achieved by GSK3β which is still in an active form in de-
phosphorylated state. Since PKC showed nuclear localization rather than being 
localized in membrane/cytosolic compartments upon activation, it could not either 
phosphorylate cytosolic tau or inactivate cytosolic GSK3β. Therefore, instead of a 
direct phosphorylation by PKC, tau was more likely to be phosphorylated by active 
GSK3β, and phosphorylation of tau caused retraction of axons. Besides its role in 
axonogenesis (Johnson and Stoothoff, 2004), p-tau takes role in microtubule re-
organization, for instance, p-tau dissociates from microtubules and these 
microtubules become more accessible and serve as substrates for microtubule 
severing protein p60-katanin (Baas and Qiang, 2005). p60-katanin’s severing activity 
is already known to increase upon tau hyper phosphorylation in terms of easier 
access onto microtubules. Consistent with morphological observations in this study 
on neuronal processes, increase was seen in the protein level of p60-katanin which 
was also in correlation with an observed increase in p-tau levels, as expected.   
In dividing cells, during the transition from interphase to mitosis, p60-katanin is 
known to increase (Karabay, 2004). Based on cyclinD1 increase upon PKC 
activation, neurons might be thought as being tricked by unconfirmed signals of 
division and therefore, they are increasing their p60-katanin level. In addition to be 
known as an indisputable marker of coming out of cell cycle, cyclinD1 also seems to 
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have a role in neuronal morphology. On the other hand, in addition to cyclinD1 
increase, whether or not PKC could transcriptionally activate p60-katanin remains to 
be further investigated. Based on our previous studies on microtubule severing 
protein p60-katanin, it is known that long microtubules are cut into shorter 
microtubules by up-regulation of p60-katanin. Besides, in neurons, p60-katanin gives 
rise to side branch increase by cutting long microtubules into shorter pieces 
(McNally and Vale, 1993). All of observations indicating the increase in process 
number and accumulation of microtubules in the cell body are consistent with p60-
katanin’s known functions in neurons. 
When it comes to p-tau and p60-katanin protein levels of neurons in Aβ treated 
conditions, phosphorylation levels were similar to control groups. Although only 
PMA treatment increased p-tau levels together with p60-katanin levels (Figure 3.12), 
there was no increase in phosphorylation state of Aβ treated neurons upon PMA 
induction (Figure 3.20). Although results inicated that Aβ did not trigger 
neurodegeneration totally under these experimental conditions, it is possible for Aβ 
to cause impairments in PKC signaling pathway and prevent activatory effect of 
PMA, consequently elevation in p-tau and p60-katanin protein levels.  
As up-regulation of cell cycle markers in neurons has been shown to ultimately cause 
apoptosis (Johnson and Stoothoff, 2004; Gasparini, 1998; Atabay and Karabay, 
2011), it was important to see if there would be any increase in apoptosis regulatory 
proteins. Balance between these proteins is thought to determine the cell fate in terms 
of death or survival. Thus, it was specifically concentrated on pro-apoptotic Bax, 
anti-apoptotic Bcl-2, and apoptotic caspase3 (Oltvai, 1993). Changes in cleaved 
PARP level that takes part in downstream of apoptotic signaling pathway was also 
analyzed. Although up-regulation of cell cycle markers in neurons has been 
associated with an increase in apoptotic proteins, findings in this study indicating an 
increase in nuclear cyclinD1 did not actually produce any considerable change in 
Bax, cleaved PARP and active caspase3 apoptotic proteins, yet there was an increase 
in the anti-apoptotic Bcl-2 protein. When Bax/Bcl-2 ratio was analyzed for Aβ 
conditions, it could be seen that Bax/Bcl-2 ratio was slightly increased indicating an 
early attempt to neurodegeneration.  
In only PMA treated neurons, although there was an increase in pro-caspase3, it 
could not be cleaved to generate active caspase3. It is likely that pro-caspase3 is 
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counteracted by the increase in the anti-apoptotic Bcl-2 to inhibit apoptosis. In 
addition to known roles of caspase3 in apoptotic perspective, recent studies 
introduced a new and provocative point of view for the roles of caspase3. D’Amelio 
et al. (2010) have shown that inhibition of caspase3 activation altered proteins that 
are related to differentiation and has dramatically reduced neurite formation. 
Morphological changes that were observed in PKC-α activated neurons, indicating 
stunt processes seem to be consistent with these newly attributed functions of 
caspase-3. 
Surprisingly, previously indicated factors, such as nuclear localization of cyclinD1 
and increase in p-tau leading neurons into degeneration did not seem to create a 
neurodegenerative pattern in PMA treated neurons in this study. For instance, in a 
previous study from our lab (Atabay and Karabay, 2011) in which Pin1 - a regulator 
of cell cycle progression - was inhibited, increases were observed in p-tau and 
cleaved caspase3 levels, and ultimately in apoptosis of neurons. Yet, in PKC 
activation, even though an increase in p-tau was observed there was no increase in 
cleaved caspase3; and in addition to this, an increase was observed in the anti-
apoptotic protein Bcl-2. Therefore, it is probably not solely the increase in cyclinD1 
that would lead neurons into apoptosis; it is rather an accompanying increase in 
cleaved caspase3 or neutralization of it by anti-apoptotic proteins that would 
determine the fate of neurons between survival and apoptosis in an emerging 
degenerative condition. Impinges on which signaling pathways in neurons cause 
activation of cell cycle related proteins and whether or not they could be modulated 
remain to be the subject of further research. 
In conclusion, in addition to its previously known roles in cell cycle regulation, PKC 
over-activation may have effects causing withdrawal from differentiation in neurons 
by increasing nuclear cyclinD1 and promoting microtubule re-organization via 
increasing p60-katanin and Aβ seems to prevent this attributed function of PKC 
probably by direct Aβ – PKC interaction through its pseudosubstrate site. 
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APPENDIX A : qRT-PCR efficiency and error rate values. 
APPENDIX B : qRT-PCR data generated by relative expression software tool. 
APPENDIX C : Data comparison table for the different experimental conditions. 
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APPENDIX A : qRT-PCR efficiency and error rate values. 
Table A.1 : qRT-PCR efficiency and error rate values. 
 
Gene  Efficiency Error Rate 
Beta actin 1.899 0.0547 
GAPD 1.968 0.00875 
cyclinA 1.973 0.0154 
cyclinB1 1.810 0.0141 
cyclinD1 1.918 0.06 
cyclinE 1.859 0.009 
cdk1 1.863 0.0290 
cdk2 1.980 00136 
cdk4 1.934 0.00980 
p27 1.889 0.00219 
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APPENDIX B : qRT-PCR data generated by relative expression software tool. 
Table B.1 : qRT-PCR data for PMA treated neurons generated by relative expression 
software tool. 
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Table B.2 : qRT-PCR data for Gö6976 treated neurons generated by relative 
expression software tool. 
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Table B.3 : qRT-PCR data for 1 h Gö6976 followed by 23 h PMA treated neurons 
generated by relative expression software tool. 
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Table B.4 : qRT-PCR data for 24 h amyloid beta treated neurons generated by 
relative expression software tool. 
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Table B.5 : qRT-PCR data for 24 h amyloid beta and 24 h PMA treated neurons 
generated by relative expression software tool. 
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APPENDIX C : Data comparison table for the different experimental conditions. 
Table C.1 : Data comparison for the different experimental conditions. 
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